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INTRODUCTION 
Bladder cancer is one of the commonest malignancies in humans, with an 
estimated 200,000 new cases per annum world wide1.It is two and half times 
commoner in males than females2. Its incidence, like most other malignancies, 
increases with age, though it can occur in any age3.  Several important risk 
factors have been identified for bladder cancer including cigarette smoking, 
exposure to chemicals such as aniline dyes, benzidine compounds, aromatic 
amines; “slow acetylators” metabolic phenotypes and the presence of chronic 
inflammation or infection of the bladder4. Histologically, greater than 90% of 
bladder cancers are transitional cell carcinomas; squamous cell cancers and 
adenocarcinomas constituting 5% to 6% and 1% respectively4. Around 70% of all 
transitional cell carcinomas are classified as superficial lesions i.e., they do not 
invade more extensively than into the lamina propria. They comprise of a 
heterogeneous group ranging in both histologic grade (low or high) and stage Ta 
confined to the mucosa, T1 invasive into the lamina propria, or CIS - carcinoma in 
situ 5. Even with early adequate treatment there is an overwhelming propensity of 
carcinoma bladder to recur. Up to 70% of superficial tumours recur within 5 
years, a figure that rises to 90% in 15 years. Over 20% of the superficial tumours 
progress to invasive disease with a poor prognosis6-7. This entails an intensive 
follow up protocol to detect recurrences at the earliest. Presently cystoscopy 
remains the primary diagnostic modality to detect carcinoma bladder.  
Cystoscopy has a reported sensitivity of over 90%8 to detect tumour 
recurrence. It however is invasive, uncomfortable and expensive, apart from the 
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loss of man hours at work and the requirement for a trained urologist. Moreover, 
the classic  recommendation for cystoscopic surveillance in bladder cancer has 
been, once every 3 months for first year, every 6 months for the second year, and 
yearly thereafter. These are authority based opinions with little empirical backing. 
Such schedules may be inadequate for high risk patients and overzealous for 
individuals with solitary, low grade, low stage lesions9. It is also limited by low 
specificity and positive predictive value when used to evaluate lesions occurring 
in the bladder during the follow up of patients with TCC bladder.8 
To detect carcinoma of the urinary bladder noninvasively at initial 
presentation, or at follow up cytological assessment remains the standard 
assay10. It is however plagued by low sensitivity, on an average less than 50%; 
and as low as 30% in low grade, low stage disease8. It is a laboratory based 
investigation, cumbersome and expensive, requiring trained personnel for its 
interpretation, with slow sample collection and minimal potential for automation. 
Bladder cancer is a chronic illness with no definite and suitable curative 
measures. The main goal in their management is to diagnose the primary and 
recurrent tumour as early as possible, while it is amenable to local resection. 
Urine Cytology 
Urinary cytology is the study of cells from the bladder and the upper 
urinary traact. Bladder cells are obtained from voided urine or from lavage fluid. 
Usually, three specimens are acquired for analysis. Urine cytology is especially 
useful in diagnosing transitional carcinoma in situ (TIS) and high-grade 
transitional cell carcinoma (TCC). In fact, urine cytology is positive in roughly 
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95% of patients with high-grade tumors. Unfortunately, urine cytology does not 
detect low-grade lesions very well, since cellular changes often are very subtle 
in early malignancy; only about one-third of all cytologic findings for low-grade 
lesions are positive. Urine cytology features that suggest cancer include13:  
• Increased nuclear to cytoplasmic ratio  
• Irregular nuclear border   
• Hyperchromasia   
• Irregular clumping of chromatin  
• Abnormal location of the nucleus (cell center)  
• No cytoplasmic vacuolization (spaces within the cell fluid)  
In addition, small percentages (1% to 12%) of cytology findings are "false 
positive". False-positive cytologic results may be caused by factors such as 
inflammation or changes brought on by radiation therapy or chemotherapy11-20.  
Urine cytology complements cystoscopy by offering high sensitivity for the 
detection of high-grade TCC. However, the accuracy of urine cytology appears to 
be associated with considerable variability. Positive results are obtained in 31–
72% of patients with bladder cancer, when all tumour grades and stages are 
considered11–20. The sensitivity is highly dependent on tumour grade 7, 9, 10. Low-
grade tumours are not reliably detected by cytology, whereas high grade tumours 
are detected 79% of the time 7, 9, 10. Variations in the histological criteria of 
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malignancy in bladder tumours, differences in the preparation techniques of 
smears, suboptimal specimen quality and differences in pathologists expertise 
with the test have been offered as possible explanations 17. These difficulties are 
compounded by artefactual changes that may be introduced by infection, 
catheterization, electro cauterization, bladder washing, previous intravesical 
therapy or previous radiotherapy 18. These variables affect the urothelium and 
may undermine the sensitivity of cytology 18. For example, Wiener et al. 18 
reported 71.4% accuracy in newly diagnosed tumours versus 44–50% after 
transurethral resection, radiotherapy or intravesical therapy. 
Therefore many variables might decrease the ideal performance 
characteristics of urinary cytology; thus we explored the ability of urinary cytology 
to predict an established recurrence of previously known non muscle invasive 
TCC and to objectively evaluate the difference in cytologic findings 
between specimens of voided and barbotage sample of urine. 
This study is an attempt to review the practice of urine cytology 
examination in our setting of nonavailability of trained cytopathologist at all point 
of time and also to assess whether a barbotage sample of urine gives a better 
yield for diagnosis of nonmuscle invasive TCC bladder during the follow up. 
 
 
 
5 
 
REVIEW OF LITERATURE 
Urine Cytology:  
The microscopic evaluation of urinary sediment dates back to the 19th 
century when Sanders48 and Dickenson49 described the presence of abnormal 
cellular findings in the urinary sediment of men who were subsequently 
diagnosed with bladder cancer. However, it was not until the mid-20th century that 
modern urine cytology was introduced by Papanicolaou and Marshall 54 and more 
formally applied in the clinical detection of bladder cancer. During the past 20 
years, the use and utility of urine cytology in the diagnosis and management of 
urothelial carcinomas has become commonplace and, in some instances, a 
standard of practice. Since the first satisfactory technique for demonstrating 
cancer cells in centrifuged urine was described by Papanicolaou and Marshall in 
1945, urine cytology has been an integral part of cancer screening. Several 
requirements must be met for urinary tract tumours to be detected by cytology. 
Since it is based on the evaluation of morphological variables of the exfoliated 
cells, there must be contact between the lesion and urine, the lesion must 
regularly shed cells and these cells must be sufficiently different from normal cells 
to be identified14. Important intrinsic tumour factors that affect cytology include 
tumour grade, configuration (multicentricity, stage) and location (upper or lower 
tract). Interpretation of the urine specimen can be challenging, especially when 
urolithiasis and instrumentation are factors and it is observer dependent15. The 
analysis is most successful when the sample is immediately transported to the 
cytology laboratory for preparation. Improper handling and delay in transfer may 
result in the destruction or degradation of cells.  
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Application and collection of urine cytology by urinary tract site50 
Site Specimen Comment 
Bladder 
Screening for high-risk 
patients (hematuria, 
carcinogen exposure, 
irritative symptoms) 
Voided Late morning void preferred 
Diagnosis of primary 
malignancy and precursor 
Lesions 
Catheterization/ 
endoscopy 
Avoids skin/urethral 
contamination 
Diagnosis of secondary 
malignancy (metastases, 
direct extension, 
fistulization) 
Wash/barbotage Specific to bladder,increased diagnostic yield 
Surveillance after therapy 
for primary tumor (surgery, 
immunotherapy, 
chemotherapy) 
Surveillance after therapy 
for upper tract tumor 
  
Urethra 
Surveillance of urethral 
remnant after 
cystectomy 
 
Voided 
 
Wash 
Surveillance after 
cystectomy/orthotopic 
Neobladder 
Surveillance after 
cystectomy/cutaneous 
diversion/urethral remnant 
Renal pelvis/ureter 
Screening for high-risk 
patients 
Voided Nonspecific, low yield 
Diagnosis of primary 
malignancy and precursor 
lesions 
Catheterization Specific to side and level in urinary tract 
Surveillance after therapy 
for primary upper 
tract lesion (eg, after 
endoscopic therapy) 
Wash Increases diagnostic yield 
Surveillance of upper tract 
after cystectomy Brushings 
Direct exfoliation of 
suspicious area 
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While cytology has a reported specificity of greater than 93%, its sensitivity 
is only 25-50%, particularly for the detection of low grade and low stage tumours. 
However, this sensitivity increases considerably in detecting carcinoma in situ 
(CIS) and high grade and high stage transitional cells carcinomas and it is in this 
group of patients that it proves particularly useful. The poor accuracy in the 
detection of low grade, low stage tumours confines it to use as an adjunct 
alongwith cystoscopy in diagnosing bladder cancer10. 
Diagnostic yield of urine cytology in malignancy 50 
 True-Positive Cytologic Findings (%)* 
Tumor Grade Voided 51,52 Bladder Wash 53 
1 17 70 
2 72 98 
3 94 100 
CIS 100 100 
* “Suspicious” and “positive” diagnoses but not “dysplasia.” 
Urine cytology is undeniably inadequate and is plagued by low sensitivity 
and subjective diagnostic criteria for the majority of lesions. Additionally, 
duplication of the three-tiered grading system is difficult cytologically. 
CYTOLOGY OF NONMUSCLE INVASIVE BLADDER CANCER 
In patients who are screened for bladder cancer, the overall sensitivity of 
positive urine cytology is approximately 40% to 6O%." (21, 30) A positive cytologic 
diagnosis is highly predictive of TCC, even in the presence of normal 
cystoscopy.24 Malignant cells may appear in the urine long before any 
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cystoscopically detectable lesion emerges, 26 leading to a seemingly inflated rate 
of false-positive results. One variable affecting the sensitivity of urine cytology is 
the type of specimen.  
Voided urine specimens are generally hypocellular and degenerated. They 
may also contain significant amounts of skin and vaginal contamination, 
particularly when collected from female patients. The sensitivity is augmented 
when three specimens are obtained on three separate days. For one, two, and 
three voided urine specimens, sensitivities of 41%, 41% and 60% have been 
reported, respectively.26'  
Catheterized urine and bladder washes have higher cellularity and less 
contamination but require an invasive procedure that may introduce 
instrumentation artifact.25  
All urine cytology specimens are sufficiently dilute as to require some form 
of cell concentration. Initially, cytologic findings were assessed on smears made 
from the sediment of centrifuged specimens27. Subsequently developed methods 
include thin membrane filtration, cytocentrifugation, and, most recently, 
monolayer technology. Malignant cells identified in cytologic specimens may 
come from either low-grade or high-grade lesions. Cells designated as low grade 
should correlate with histologic grade I lesions and some histologic grade TI 
lesions. Cells designated as high-grade correlate with some grade 2 lesions and 
all grade 3 lesions but also with TCC in situ.26 
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High-grade Transitional Cell Carcinoma and Transitional Cell Carcinoma In 
Situ 
Urine cytology has excellent performance statistics in patients with high-
grade lesions, which is the primary reason for its continued efficacy as a 
screening and surveillance device. The sensitivity is at least 90%, and the 
specificity reaches 98% to 100%.22,26 The cytomorphologic features are well-
characterized and easily recognized, leading to cytologic designations of “positive 
for malignant cells” in most cases and ”suspicious for malignancy” in some. 
Tumor cells are larger than normal with increased nuclear-to-cytoplasmic (N / C) 
ratios and eccentrically placed nuclei. Pleomorphism is evident, and individual 
nuclei have irregular membranes and often prominent nucleoli. Marked nuclear 
hyperchromasia is present, as well as coarse irregularly distributed chromatin, 
frequent mitotic figures, and vacuolated amphophilic cytoplasm22, 26 
Low-grade Transitional Cell Carcinoma and Dysplasia 
The overall low sensitivity of urine cytology is explained almost exclusively 
by its unreliable detection of well-differentiated, low grade lesions. Because the 
cells of such tumors so closely resemble normal urothelium, cytopathologists opt 
for terminology such as ”atypical urothelial cells present; cannot rule out a low-
grade lesion.” Much effort has focused on identifying features to aid in the 
distinction between normal urothelial cells and well-differentiated malignant cells.  
According to the review of the literature by Renshaw and co-workers in 
‘The cytology of low-grade urothelial neoplasm’s’, this review has showed 
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sensitivities ranging from 0% to 100% and specificities ranging from 6% to 
100%.31 
D eMay22 mentions the presence of varying numbers of single small "coy 
cells" in the background that have very high N/C ratios and abnormal slightly 
hyper chromatic nuclei with slightly coarse chromatin and irregular nuclear 
membranes. Using stepwise logistic regression analysis  Raab and co-workers28 
identified the three criteria most useful in discriminating low-grade TCC from 
nonneoplastic processes : 
1) cytoplasmic homogeneity, defined as the absence of cytoplasmic 
vacuoles; 
2) an increased N/C ratio, defined as greater than 1 to 3; and  
3) irregular nuclear borders.  
When at least two of the three criteria were present,  the sensitivity was 85% and 
the specificity 96% when applied retrospectively.28 
INCREASING THE SENSITIVITY OF CYTOLOGY 
Perhaps the greatest determinant of the sensitivity of urine cytology is the 
level of Cytopathologist  expertise. Nevertheless, much effort has focused on 
developing ancillary techniques to improve the sensitivity of urine cytology. Of the 
large variety of methods tested, techniques for detecting nuclear aneuploidy, the 
presence of cell markers such as Lewis X antigen, and over expression of p53 
seem most promising.30 
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A review of urine cytology in the diagnosis and follow up of bladder cancer 
at Roswell Park Memorial Institute from 1971 to 1981 was reported by Zein TA et 
al. All patients had biopsy-proven transitional cell carcinoma of the bladder. A 
total of 677 patients underwent 2,877 cytological evaluations. Of these, 317 
patients had concomitant cystoscopy, cytologic evaluations and bladder biopsies. 
A total of 1,091 evaluations were performed in this group. The overall incidence 
of positive cytology in the presence of biopsy-proven baldder tumor (all grades 
included) was 74.4%32. A linear correlation is present with grade, stage and 
positive cytology; high-grade tumors and carcinoma-insitu showed 89.9% and 
96.9% incidence of positive cytology, respectively. Grade II tumors showed a 
64% incidence of positive cytologies. Regarding correlation with the pathological 
stage, submucosal involvement of the urothelium was associated with a 62% 
incidence of positive exfoliative urine cytology, while 80% of tumors invading the 
bladder muscle were found to have a positive cytology32. 
Mungan NA et al from the Department of Urology, Numune Hospital, 
Ankara, Turkey did a study to assess the sensitivity of urine cytology by using 
different portions of voided urine cytology (VUC) and bladder wash material 
cytology (BWC).  
52 patients with biopsy-proven superficial transitional cell carcinoma (TCC) 
the bladder were studied. Voided urine specimens were divided into a first 
stream, mid-stream and terminal stream. Bladder wash material was also divided 
into a first portion, mid-portion and last portion. All portions were investigated for 
cytology abnormalities. 
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Sensitivity for the detection of malignant cells was 34.6, 38.5 and 38.5% 
for the first, mid- and terminal stream of VUC and 34.6, 38.5 and 34.6% for the 
first, mid- and last portion of BWC, respectively. The sensitivity of VUC was 20-
25% for grade I, 30-40% for grade II, and 50-75% for grade III tumors, 
respectively. The sensitivity of BWC was 25% for grade I, 35-45% for grade II, 
and 33-50% for grade III tumors, respectively. There was no statistical significant 
difference for sensitivities between either grades (p = 0.06) or portions or streams 
(p = 0.3) of VUC and BWC33. 
Robert S et al from University of Texas Southwestern Medical Centre, 
Dallas, Texas conducted a retrospective study   to evaluate the accuracy of 
cystoscopy and cytology in predicting the histopathologic features of suspicious 
cystoscopic lesions. They reviewed the bladder biopsy records and cytology at 
two institutions from July 2001 to July 2004. Intraoperative biopsies were 
performed for positive (papillary or sessile) (n = 155) and equivocal (n = 101) 
lesions found during office cystoscopy. For patients without a history of TCC, 
cytology had a sensitivity and specificity of 66.7% and 100%, respectively. The 
PPV of cytology in identifying cancer at biopsy was 100% (30 of 30). In contrast, 
cytology was falsely negative in 15 (63%) of 19 patients. The sensitivity, 
specificity, NPV, and PPV for cytology in patients with a history of TCC was 
63.2%, 70%, 22%, and 92.3%, respectively. For all patients with positive lesions, 
false-negative cytology findings were identified in 36 patients. Of these 36, 27 
(75%) had low-grade tumors at biopsy and 9 (25%) had high-grade tumors at 
biopsy. Those lesions with atypical cytology had normal pathologic findings in 3 
(21%) of 14 of those with a history of TCC and in 0 of 8 of those without a history 
of TCC34. 
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Planz B et al from Golzheim Paracelsus clinic, Friedrich-lau-Str. 
Duesseldorf, Germany prospectively studied the value of urine cytology in the 
diagnosis of bladder cancer. One thousand three hundred and eighty voided 
urine and bladder wash specimens of 495 patients were evaluated by urine 
cytology. In this study urine cytology revealed a sensitivity of 38% and a 
specificity of 98.3% with a positive and negative predictive value of 90.6% and 
78.6% respectively. Sensitivity increased significantly with malignancy grade. In 
high grade tumors sensitivity improved from initial 52.2% to 78.3%.In sensitivity 
and specificity of voided and barbotage washing samples no significant difference 
was detected. 
Renshaw AA et al from Brigham and Women’s Hospital, Boston, 
Massachusetts, USA in there study on urine cytology in grade 1 TCC, the 
sensitivity ranged from 22 to 44% and specificity from 69% to 85% and positive 
predictive values from 59% to 66%31 
Karakiewicz PI, et al from Department of Urology, University of Montreal, 
Montreal, Quebec, Canada did a retrospective study to assess the contemporary 
inter-institutional accuracy of urinary cytology in predicting the recurrence of 
transitional cell carcinoma (TCC) of the bladder, in a large multi-institutional 
cohort from four continents. Ten institutions contributed 2542 patients with a 
history of superficial TCC, of whom 898 had TCC recurrence. Age- and gender-
adjusted logistic regression models were used to evaluate the association 
between urinary cytology and TCC recurrence. Cytology was positive in 19 (10-
38)% of patients; recurrence was identified in 35 (27-54)% of patients35. The 
sensitivity was 38-65% across institutions. Urinary cytology varied significantly in 
14 
 
its ability to predict recurrence of bladder cancer. Institution-specific predictive 
accuracy adjusted for gender and age was 0.627-0.893. Stratifying by grade and 
stage only partly attenuated the discrepancies between centre’s35. 
Loh CS et al from Department of Urology and histopathology, Broadgreen 
Hospital NHS trust, UK did a prospective study to evaluate the value of exfoliative 
urine cytology in predicting recurrent tumour in patients undergoing surveillance 
for TCC. The study comprised 111 patients (85 men and 26 women) with an 
established histological diagnosis of TCC of the urinary bladder who were 
assessed over an 8-month period. Each patient was asked to submit a specimen 
of early-morning urine and freshly voided urine 2 weeks before the planned 
review cystoscopy. From 111 patients, 118 assessments met the full criteria for 
inclusion in the study. Malignant cells were reported in one or both of the paired 
urine specimens in 29 cases, being positive in both the early morning urine and 
freshly voided  urine specimens in 24 of these. Typical cells were found in one or 
both specimens in 34 cases, being present in both the early morning urine and 
freshly voided urine specimens in 24 instances; 38 paired specimens were 
considered to show normal cytology, a further five were normal in one specimen 
only, and in 12 cases both the  early morning urine and freshly voided  urine 
specimens were considered undiagnostic36. 
Of the 118 cystoscopies, 56 revealed abnormal mucosa, the biopsies of 
which were neoplastic in 39 specimens, with TCC in 34, moderate epithelial 
dysplasia in three, mild dysplasia in one and adenocarcinoma of prostate in one.  
The other 17 biopsies revealed radiation changes in four, chemotherapy changes 
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in two, chronic inflammation in eight, an inadequate biopsy specimen in one and 
no significant histological abnormalities in two. 
The outcome after cystoscopy and biopsy in cytologically positive and 
negative patients is shown in tables 1 and 2, respectively.  
Urine cytology positive 
 Malignant cells 
(n [%] ) 
Atypical cells 
(n [%] ) 
Total 
(n [%] ) 
Normal cystoscopy 7(11) 17(27) 24(38) 
Recurrent TCC 17(27) 10(16) 27(43) 
Dysplasia  1(2) 3(5) 4(6) 
Prostate adenocarcinoma 1(2) 0 1(2) 
Chemotherapy changes 2(3) 0(0) 2(3) 
RT changes 0(0) 2(3) 2(3) 
Inflammation  1(2) 2(3) 3(5) 
Total  29(46) 34(54) 63(100) 
 
Urine cytology negative 
 Normal cells 
(n [%]) 
Non-diagnostic cells 
(n [%]) 
Total 
(n [%]) 
Normal cystoscopy 29(53) 9(26) 38(69) 
Recurrent TCC 5(9) 2(4) 7(13) 
RT changes 2(4) 0(0) 2(4) 
Inflammation 5(9) 0(0) 5(9) 
Normal biopsy 1(2) 1(2) 2(4) 
Biopsy undiagnostic 1(2) 0(0) 1(2) 
Total  43(78) 12(220) 55(100) 
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Of the 29 instances where malignant cells were present in one or both of 
the paired urine specimens, 22 had abnormalities at cystoscopy. Seven patients 
with malignant cytology had no mucosal abnormality at cystoscopy. One was 
later found to have prostatic adenocarcinoma, one had a bladder calculus and 
two were thought on subsequent review to have had normal cytology, degenerate 
urothelial cells being mistaken for malignant cells. 
Of the 34 cases with atypical cells in one or both of the paired urine 
specimens, 17 had abnormalities at cystoscopy. The other 17 cases with atypical 
cells at cytology showed no abnormality on cystoscopy. 
In 43 cases with normal cytology, cystoscopic abnormalities were preset 
14 cases; there were 12 cases in which both the urine specimens were deemed 
undiagnostic on cytology.  
The sensitivity of urine cytology in identifying all tumours and dysplasia 
was 32/39 (82%) with a specificity of 32/63 (51%). Table 3 shows the sensitivity 
of urine cytology compared with the histopathological stage and grade of the all 
the recurrent TCC . In this small group of patients, the sensitivity was higher in 
high grade (G2/G3) TCC. 
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Urine cytology results for the histological grades/stages of recurrent TCC 
Grade/stage number Positive cytology 
Sensitivity 
(%) 
G1/pTa 10 6 60% 
G2/pTa 10 8 80% 
G2/pT1 4 4 100 
G3/pT1 3 2 67 
G3pT3 1 1 100 
G3/pTis 6 6 100 
Total 34 27 79 
 
This study has shown a high rate of detection of recurrent TCC using 
exfoliative urine cytology which was more pronounced with tumors’ of higher 
grade and stage compared with those of lower grade. All the patients with 
dysplasia had abnormal cytology. On the other hand there was a high level of 
false positive results, with 24 of 63 having normal mucosa at cystoscopy and 31 
of 63 being normal or having non-neoplastic abnormalities. 
Tawfik Zein et al37, from Department of Urologic Oncology and Pathology, 
Roswell Park Memorial Institute, Buffalo, New York, did a prospective study of 
136 patients with biopsy proven bladder tumor who underwent 311 evaluations 
with cystoscopy, urinary cytology, bladder washing and, bladder biopsies. 
Of the 136 patients 89 had bladder biopsies positive for transitional cell 
carcinoma at the time of the study and were evaluated for comparison of urinary 
cytology and bladder washing. The remaining patients had a history of bladder 
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tumour  and were followed for recurrent disease. Urinary cytology and bladder 
washing specimens were positive in 71 and88 per cent of the cases, respectively. 
Concomitant urine and bladder washing specimens were available in 73 
patients with Histologically proved TCC and the results were compared according 
to tumour grade.(table 1). Cytology studies also were obtained in 54 patients in 
whom bladder mucosal biopsies showed dysplasia only without evidence of 
tumour. Of these 54 patients 33 had concomitant bladder washing and urinary 
cytology studies, including 30 with moderate dysplasia pathologically who also 
were evaluated cytologically. The results in the latter 30 patients showed a 
significant increase of abnormal cells in the bladder washing specimens(9 
patients, 30 per cent) compared to those obtained by urinary cytology(5 patients, 
16.6 per cent). There was a 23 per cent incidence of random biopsies positive for 
carcinoma in situ. Of these patients 10 had a high grade primary tumour and 
multiple biopsies were positive in 55 per cent , while 9 with a low grade primary 
tumour had a 10 per cent evidence of carcinoma in situ. 
The superiority of the bladder washing over urinary cytology might be attributed 
to, 
1. Better preservation of cells,43 
2. Less contamination in the background,38 
3. Better preservation of the bladder epithelium,38 
4. More details of nucleus and cytoplasm,43 
5. Immediate fixation,44 
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Table 1 Bladder tumour according to grade and cytological correlation with 
negative, positive and suspicious interpretations 37 
Urine cytology (%) 
Bladder washing (%) 
positive negative suspicious
Grade  No.tumors positive negative suspicious
31 37 22 
1 16 25 50 25 
2 21 57 4 39 85 4 11 
3 23 74 0 26 87 0 13 
Ca in 
situ 
13 77 15 8 85 7 8 
  
Table 2 Comparison of urine cytology and bladder washing results 
according to grade. 
References No. of Pts Grade % pos.cytology 
% pos.bladder 
washings 
Harris et al (38) 20 
2 40 80 
3 60 100 
Eposti et al (39) 195 
1 - 28 
2 - 76 
3 - 89 
National bladder cancer 
Collaboration Group A(40) 114 
1 13 40 
2 39 35 
3 77 88 
MacFarlane, Ceelen, 
Taylor et al (41) 119 
Low 55 - 
High 88 - 
Dubernard, Devonec, 
Amiel, Bouvier et al (42) 51 
1 9 - 
2 75 - 
3 93 - 
Tawfik Zein et al (37) 73 
1 25 31 
2 57 85 
3 74 87 
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These studies demonstrate the superiority of bladder washings over urinary 
cytology in detecting abnormal cells and malignant cells in patient with TCC 
bladder. 
NEW HORIZONS IN URINARY TESTS FOR UROTHELIAL CARCINOMA 
FLOW CYTOMETRY 
Voided urine cytology does not contain enough cellular content; therefore, 
flow cytometry uses specimens obtained by bladder wash through a catheter or 
cystoscope. Flow cytometry seeks to detect aneuploid cells as a marker of 
underlying malignancy.55 Recent studies comparing flow cytometry with 
conventional urine cytology have demonstrated perhaps only a marginally 
increased sensitivity, but significantly lower specificity.56,57 
Ancillary techniques to improve the sensitivity of urine cytology have been 
insufficiently additive to have much clinical value. Several promising bladder 
tumor markers have been investigated as potential screening tools and are 
summarized in Table 3. BTA, nuclear matrix proteins, and fibrin / fibrinogen 
degradation products share lower specificities han urine cytology and may have 
high rates of false positivity. Telomerase is highly sensitive and highly specific but 
is not readily available as a point-of-service test. Hyaluronidase and hyaluronic 
acid are promising prognostic markers, but hyaluronidase does not detect grade I 
TCC. Early results from studies of this marker await verification. Combining some 
of these new markers may optimize their performance status, allowing the 
advantages of one test to correct the shortcomings of another. Likewise, their 
combination with urine cytology may prove beneficial. Although adding urine 
cytology has not increased the sensitivity of some point-of-service tests, few 
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studies have addressed the effect on specificity. Until an obvious winner is 
declared in the race to find a bladder tumor marker, urine cytology will remain the 
gold standard screening method because of its comfortable familiarity. 
Table 3. POTENTIAL MARKERS OF BLADDER CARCINOMA 58 
Test Detects Sensitivity Drawbacks
Bard BTA Lysed basement 
membrane 
components 
29% to 40% Low detection of 
grade I TCC 
Poorer predictive 
value than urine 
cytology 
BTA stat Human 
complement factor 
H-related antigen 
67% to 87% High false-positive 
with gross 
hematuria, 
prostate cancer, 
BCG 
BTA TRAK Human 
complement factor 
H-related antigen 
72% High false-positive 
with UTI, stones, 
instrumentation 
NMP22 Nuclear matrix 
proteins 
66% High false-positive 
with gross 
hematuria 
AuraTek FDP Fibrinogen, Fibrin/ 
fibrinogen 
degradation 
products 
48% to 68% High false-positive 
with gross 
hematuria 
Telomerase Telomerase 
activity 
70% False-negatives 
with gross 
hematuria 
False-positives 
with inflammation 
Hy aluronic acid 
 
Hyaluronic acid 92% Too early to 
substantiate 
results 
Hyaluronidase 
 
Hyaluronidase 
activity 
100Y" No detection of 
grade I TCC 
 BTA = bladder tumor antigen; TCC = transitional cell carcinoma; BCG = bacillus 
Calmetle-Guerin; UTI = urinary tract infection. 
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Aims and Objective 
1. To assess the accuracy of urinary cytology of voided urine sample in 
predicting the recurrence of non-muscle invasive transitional cell 
carcinoma (TCC) of the bladder. 
2. To assess the accuracy of urinary cytology of barbotage urine sample in 
predicting the recurrence of non-muscle invasive transitional cell 
carcinoma (TCC) of the bladder. 
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MATERIAL AND METHODS 
Study Design: Prospective Study 
Duration of study:1st August 2009 to 31st January  2011 (eighteen           
months) 
Patient Characteristics: 
One hundred and ninety two patients from the inpatients and outpatients, 
of the Department of Urology, CMC, Hospital, Vellore, Tamil Nadu were enrolled 
into the present study. 
Inclusion Criteria:  
1. Patients with biopsy proven TCC undergoing follow up cystoscopy after 
initial diagnosis.  
2. A functioning bladder, free of any concurrent non-bladder urological 
cancers.  
3. Sterile urine culture. 
Exclusion Criteria8: 
1. Patients with non-bladder urological malignancies. 
2. Non-biopsy proven cases. 
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3. Gross haematuria. 
4. Benign inflammatory or untreated infectious conditions. 
5. Renal, bladder or ureteric calculi. 
6. Recent history of a foreign body in the urinary tract.  
7. History of bowel segment interposition in the urinary tract. 
Informed consent was taken in all cases. The urine was cultured to detect 
urinary tract infection. If the culture was positive, an appropriate culture sensitive 
antibiotic was administered for 5 days. 
The study cohorts comprised 192 patients and were followed with office 
based cystoscopy and voided urinary cytology and barbotage urinary cytology. Of 
this 192 patients 35 came for review twice, 10 came for review thrice and only 
one had four reviews. Hence the numbers of cystoscopies were 250 and cytology 
specimens were 250 of voided urine sample and 250 of barbotage urine sample 
each. Patients were included at various stages of follow-up and the number of 
recurrences before inclusion varied from none to several. Voided urine sample 
and barbotage urine sample for cytology was obtained before cystoscopy. 
For voided samples, a midstream collection into a clean container was 
advised to the patients. No fixatives were added if they were processed 
immediately. However, an equal amount of 50% ethanol was added as 
preservative and the specimen was refrigerated if there was delay in processing 
the urine sample. 
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Barbotage sample was obtained by washing the bladder through the 
cystoscope sheath via a 50 cc syringe with 100 cc normal saline. The sample 
obtained was immediately sent to the laboratory for processing. 
Cystoscopy was done with a17 French ACMI or integrated Miller scope 
under local anesthesia. Suspicious lesions in the bladder were biopsied using a 
cold cup biopsy forceps or if the tumour was large the patient underwent 
transurethral resection of the tumour under anaesthesia. . The biopsies were 
placed in 10% formalin and sent for histopathological examination 
Urine sample was centrifuged at a rate of 1800 RPM for thirty minutes and 
the supernatant urine was discarded. The centrifuged urine sediment was 
resuspended with 2 drops of bovine albumin mixed well, transferred 0.5ml of this 
mixture into 2 chambers, and cytospined at 800rpm for 5 minutes After 
centrifugation the cell sediments at the bottom of the tube was transferred to a 
glass slide and was stained by  the Papanicolaou method and examined under a 
light microscope. If it is blood stained, Carnoy’s fixative was used. By this 
method, the cytoplasm of transitional cells stains greenish-blue and the nuclei are 
purple. 
The Papanicolaou stained slides were read by a panel of cytopathologist.  
Malignant and atypical cells were assessed according to the criteria of Koss45.  
Malignant cells showed large hyper chromatic nuclei with coarse chromatin and 
often occurred in clusters, while atypical cells were regarded as those with 
enlarged nuclei showing slight to moderate hyperchromasia but not exhibiting the 
full nuclear abnormalities of malignancy. Specimens were reported as containing 
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malignant cells, atypical cells, no abnormal cells, or unsuitable for diagnosis. A 
specimen was judged to be non-diagnostic when there were too few cells present 
for assessment; the cells were obscured by inflammatory cells or debris or when 
the specimen was poorly preserved. 
The various description of the histopathological examination of the slide 
were as follows: 
Unsatisfactory specimen. This meant that not enough cells or the 
nontransitional types of cells were found in urine sample.  
Negative. This means no cancer cells were identified in urine sample.  
Atypical. This indicates some changes were found in the cells in urine sample. 
But while the cells weren't normal, they weren't abnormal enough to be 
considered cancer.  
Suspicious. This term may indicate that urine cells were abnormal and may be 
cancerous.  
Positive. A positive result indicates that cancer cells were found in urine.  
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All tumors were graded according to World Health Organization (WHO) 
1998 grading46. They were staged according to the Tumor Node Metastasis 
(TNM) system of AJCC47.  
 
Figure 1. Urine cytology stained by the Papanicolaou procedure.    Normal 
cytology  with no mitotic activity and normal nuclear-to-cytoplasmic ratio 
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Figure 2. Urothelial cells showing slight atypia with increased nuclear-to-
cytoplasmic ratio. Magnification x 40 
 
Figure 3. Urothelial cells showing slight atypia with increased nuclear-to-
cytoplasmic ratio. Magnification x 10 
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Figure 4. Severe urothelial atypia that is characteristic of bladder cancer, with 
varying cell size, increased nuclear-to-cytoplasmic ratio and an abnormal 
chromatin pattern. 
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OBSERVATIONS AND RESULTS 
1. AGE AND SEX DISTRIBUTION 
192 patients were enrolled in the study. There were 172 males and 20 
females (Figure: 1). The patient’s age ranged from 27 to 81 years with a mean 
age of 55.57 years. The majorities, 71 patients (36.97%), were between 41 -50 
years of age (Table: 1, Figure: 2). 
 
 
                                                                Figure:1 
  
90%
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Sex distribution of the patients (n = 192)
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Table: 1 AGE DISTRIBUTION OF THE STUDY POPULATION (n= 192)  
Age Range Number of patients Percentage 
21  --  30 15 7.81 
31  --   40 43 22.39 
41  --   50 71 36.97 
51  --   60 46 23.95 
61  --   70 13 6.77 
71  --   80 3 1.56 
81  --   90 1 0.52 
 
 
 
Figure: 2 
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Stage distribution  
All patients had previous, histologically confirmed, TCC with no evidence of 
muscle invasion (stages Ta, T1 and/or CIS) and were followed with office based 
cystoscopy and voided urinary cytology. Patients were included at various stages 
of follow-up and the number of recurrences before inclusion varied from none to 
several. 
All 192 patients had non-muscle invasive TCC of the bladder. 
 
STAGE AT DIAGNOSIS: Of the 192 patients 82(42.70%) had pTa and 
110(57.29%) had pT1 stage (Figure: 3). 
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GRADE DISTRIBUTION 
INITIAL GRADE DISTRIBUTION: Initially out of the 192 patients, 
120(62.5%) patients had a low grade tumour and 72(37.50%) patients had a high 
grade tumour (Figure: 4). Eighteen patients(25%) with high grade tumour had 
associated carcinoma in situ. 
 
From 192 patients, 250 assessments met the full criteria for inclusion in 
the study, providing 250 paired specimens of urine and 250 cystoscopic 
assessments of the bladder. 
Of the 250 cystoscopies, 43 (17%) revealed abnormal mucosa on 
cystoscopy. The biopsies of which were neoplastic in 31 (72%) specimens, 
reported as TCC, 7 of the biopsies were reported as chronic cystitis, 3 were 
reported as BCG cystitis and 2 of the patients who showed small papillary 
tumours of 2-3 mm were fulgurated and biopsy was not sent. The stage and 
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grade of the primary tumour and the recurrent tumours were as shown in the 
table 2. 
 
 
 
 
Table:2 Histopathology of the primary and the recurrent tumours (n=31) 
 
Primary tumour Recurrent tumour Number of patients 
(%) 
pTaG2 pTaG2 15 (48%) 
pT1G2 pT1G2 05 (16%) 
PT1G3 pTaG2 01 (3%) 
pT1G2 PT1G3 01 (3%) 
PT1G3 PT1G3 07 (24%) 
PT1G3 CIS 02 (6%) 
 
 
 
 
 
 
 
 
Fig 5: Cystoscopy findings  n=250
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Table:3 Cystoscopically  suspicious lesion  but negative on HPE n= 12 
Chronic cystitis                                          : 7 
BCG cystitis                                        : 3 
Fulguration  
(small tumour not sent for biopsy)             : 2 
 
 
Table : 4 Sensitivity of the voided and barbotage sample of urine Grade 2 
tumours 
Stage & 
grade of 
recurrent 
tumor 
No. of 
patients 
Positive 
cystoscopy
Urine cytology 
positive Sensitivity 
Voided 
sample 
Barbotage 
sample 
Voided 
sample 
Barbotage 
sample 
TaG2/T1G2 21 21 5 12 23% 57% 
 
 
 
 
 
Fig 6: Distribution of reccurent tumours
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Table : 5 Sensitivity of the voided and barbotage sample of urine Grade 3 
tumours and CIS 
Stage & 
grade of 
recurrent 
tumor 
No. of 
patients 
Positive 
cystoscopy
Urine cytology 
positive 
Sensitivity 
Voided 
sample 
Barbotage 
sample 
Voided 
sample 
Barbotage 
sample 
T1G3 8 8 6 4 75% 50% 
CIS 2 2 1 1 50% 50% 
 
  
Table : 6 Sensitivity of the voided and barbotage sample of urine for all 
grades of tumour 
No. of 
patients 
with 
recurrent 
tumour 
Positive 
cystoscopy 
Urine cytology positive Sensitivity 
Voided 
sample 
Barbotage 
sample 
Voided 
sample 
Barbotage 
sample 
31 31 12 17 38% 54% 
 
 
Thirteen samples of voided urine cytology showed atypical cells and ten 
samples of barbotage urine cytology showed atypical cells in patients with normal 
cystoscopy. Four voided urine sample and three barbotage urine sample were 
with scanty cells and unsatisfactory for cytological assessment. Ten of the 
thirteen samples of voided urine cytology which was false positive were in patient 
whose primary tumour was T1G3 or multiple recurrence of T1G2 and had 
received BCG. Eight of the ten samples of barbotage urine cytology which was 
false positive were also patients with high grade primary tumour who had 
received BCG. The other five samples (two barbotage and three voided urine 
sample) which were false positive were in low grade tumors who had not 
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received any form of intravesical chemotherapy. Upper tract evaluation of the 
patients with positive urine cytology but negative cystoscopy did not reveal any 
tumour.  They did not manifest TCC even during further follow up. 
 
 
 
 
 
 
 
 
  
Fig 7: False positive voided urine cytology
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Specificity of voided urine cytology 
True negative False positive 
Specificity 
(TN/FP+TN) 
217 13 92% 
 
 
 
Specificity of barbotage urine cytology 
True negative False positive 
Specificity 
(TN/FP+TN) 
217 10 95% 
 
 
 
Positive predictive value and negative predictive value of voided urine 
cytology for TaG2/T1G2 tumours n=21 
True 
positive 
False 
negative 
True 
negative 
False 
positive 
PPV 
(TP/TP+FP) 
NPV 
(TN/TN+FN)
5 16 217 13 54% 96% 
 
 
 
Positive predictive value and negative predictive value of voided urine 
cytology for T1G3/CIS tumours n=10 
True 
positive 
False 
negative 
True 
negative 
False 
positive 
PPV 
(TP/TP+FP) 
NPV 
(TN/TN+FN)
7 3 217 13 35% 98% 
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Positive predictive value and negative predictive value of barbotage urine 
cytology for TaG2/T1G2 tumours n=21 
True 
positive 
False 
negative 
True 
negative 
False 
positive 
PPV 
(TP/TP+FP) 
NPV 
(TN/TN+FN)
12 9 217 10 54% 96% 
 
 
 
Positive predictive value and negative predictive value of barbotage urine 
cytology for T1G3/CIS tumours n=10 
True 
positive 
False 
negative 
True 
negative 
False 
positive 
PPV 
(TP/TP+FP) 
NPV 
(TN/TN+FN)
5 5 217 10 33% 97% 
 
 
 
  
40 
 
DISSCUSION 
 There is an overwhelming propensity of transitional cell carcinoma of the 
urinary bladder to recur. About 70% of superficial tumours, which are the 
commonest type, recur within 5 years, 90% in 15 years6,7. The greatest 
challenge in the management of superficial bladder cancer is to prevent 
progression to invasive disease.  
Stage and/or grade progression occurs in a significant number of patients. 
About 25% of patients with superficial tumours will have recurrences with 
progression of grade only. These new tumours can continue to be treated 
transurethrally if they are superficial. Invasive disease requires more aggressive 
therapy, perhaps finally a radical cystectomy depending on resectability59. 
Around 10%–15% of patients with pT1 lesions60 and 2%–4% of patients with pTa 
lesions will subsequently have invasion beyond the lamina propria (Stage T2 or 
greater) 61. 
The management of carcinoma of the bladder has two main goals; to 
detect relapsing disease before the development of overt symptoms such as 
gross haematuria and pain, and to identify tumors with potential for early 
recurrence, invasion or dissemination1. Regular surveillance of patients is 
therefore, imperative. 
The current recommendation for cystoscopic surveillance is once every 3 
months for the first year, every 6 months for the second year and annually 
thereafter9. It is usually supplemented by urinary cytology which is the standard 
noninvasive in vitro test to detect recurrence10 
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Cystoscopy continues to be the reference standard for the detection and 
follow-up of bladder cancer. However, its accuracy can be reduced in certain 
situations, including poor visualization caused by inflammatory conditions or 
bleeding, an enlarged median lobe of the prostate, and bladder diverticula. 
Moreover, small and flat lesions can be difficult to detect and differentiate from 
other benign bladder lesions.(62,63) Therefore, adjunctive noninvasive tests are 
used in addition to cystoscopy. Voided urinary cytology has been the most 
popular and recommended of such tests. In addition to supplementing 
cystoscopy, it also screens the upper tracts for possible tumor recurrence. 
However, the sensitivity of urinary cytology is very low, ranging from 11% to 76% 
and the sensitivity is even lower (15% to 30%) for detecting grade 1-2 bladder 
tumors. (64, 65) Voided urinary cytology involves visual assessment of morphologic 
changes and, therefore, requires intact cells. Small tumors or well-differentiated 
tumors, or both, are less likely to exfoliate cells spontaneously, because the 
strong intercellular attachments are better preserved and the degree of 
morphologic departure from normal is less, making recognition difficult. (66) This 
results in a low sensitivity of 15% to 30% for early-stage cancer. (67, 68) The factors 
affecting the sensitivity of urinary cytology include specimen quality, number of 
exfoliated cells, and pathologist expertise. Also, inflammatory conditions of the 
bladder can confound the results. 
Despite high specificity, it is not possible to localize cancer based on urine 
cytology alone. Therefore, a positive test result always needs further 
investigations. A normal looking bladder on cystoscopy and negative bladder 
biopsy however, doesn’t exclude possibility of urothelial cancer. In positive urine 
cytology cases with normal bladder biopsy, imaging and cystoscopy should be 
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repeated since a bladder or upper urinary tract cancer may be subsequently 
detected 58.69,70. There are several other factors such as reactive changes 
secondary to infection, stone, previous instrumentation and intravesical therapy 
which are responsible for majority of false diagnosis 68. 
It is important to provide relevant clinical information (including 
instrumentation, previous treatment and the method of urine collection) in order to 
enable the cytopathologist to report with greater accuracy68 
Urinary cytology has been considered the gold standard in bladder cancer 
screening 58. Recent advances in diagnostic methods are challenging its 
usefulness. This study compared urinary cytology with pathologic findings of 
proven bladder cancer patients to determine the value of voiding and barbotage 
urinary cytology. 
The mean age of the patients being 55.57 years in the present study, is 
consistent with the fact that, though carcinoma bladder can occur at any age, it is 
generally a disease of middle age and the elderly. Lynch and Cohen3 reported a 
median age at diagnosis of TCC of 69 years in males and 71 years in females. In 
adolescents and adults younger than 30 to 40 years, bladder cancers tend to 
express well differentiated histology and behave in a more indolent fashion9. 
TCC of the bladder is 2.5 to 4 times commoner in men than in women2,3. 
The higher rates for males remain high even after adjustment for cigarette 
smoking and exposure to occupational carcinogens. Possible explanations for 
the excessive risk in males include environmental and dietary factors not yet 
identified and innate sexual characteristics, such as hormonal factors71. The sex 
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distribution in this study was a male: female ratio of 8.6:1.The study population 
was, consisting solely of patients on follow up.    
The mean (range) sensitivity of urinary cytology for high-grade bladder 
tumours is 90% 22, 26 and the specificity reaches 98% to 100%.22, 26   the accuracy 
of urine cytology appears to be associated with considerable variability. Positive 
results are obtained in 31–72% of patients with bladder cancer, when all tumour 
grades and stages are considered 11-20. Cytology has shown high accuracy in 
detecting high-grade TCC; its performance has been inconsistent in detecting 
low-grade lesions 13. Tumour grade represents the foremost determinant of the 
performance characteristics of urinary cytology. The predictive accuracy of 
cytology is also influenced by differences in the preparation techniques of 
smears, suboptimal specimen quality, and the interpretative experience and skill 
of the cytopathologist 17. 
In the present study the sensitivity of voided urine cytology for high grade 
tumour was 60% and for low grade tumours it was 23% and the specificity was 
92%. The  sensitivity of barbotage urine cytology for high grade tumour was 50% 
and for low grade tumours it was 57% and the specificity  was  95%.Urine 
cytology was read by five different pathologist. Poor to intermediate interobserver 
agreement among cytologists confirms the importance of operator bias 72. The 
present patients had appreciable heterogeneity of the risk variables, recurrence 
rates, and stages and grades of recurrent tumours. We did not use central 
pathology and cytology reviews. Therefore, the observed poor sensitivity may 
stem from differences in cytomorphological specimen interpretation, specimen 
quality, and the interpretative experience and skill of the cytopathologists. The 
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pathologists and cytopathologists were unaware of patient clinical characteristics, 
which might have decreased their ability to accurately interpret the 
cytomorphological findings. 
The low sensitivity of both voided and barbotage urine cytology regardless 
of tumour stage and grade, contradicts the accepted thought that cytology always 
performs well in high-grade and advanced-stage tumours. Our data provide a 
realistic assessment of the yield of urinary cytology which may reflect 
interpretative experience and skill of the cytopathologists. 
The comparison of sensitivity of the present study with the results of other 
studies are given in the table below 
References No. of Pts Grade
% 
pos.cytology 
% pos.bladder 
washings 
Harris et al (38) 20 
2 40 80 
3 60 100 
Eposti et al (39) 195 
1 - 28 
2 - 76 
3 - 89 
National bladder cancer 
Collaboration Group A(40) 114 
1 13 40 
2 39 35 
3 77 88 
MacFarlane, Ceelen, Taylor 
et al (41) 119 
Low 55 - 
High 88 - 
Dubernard, Devonec, Amiel, 
Bouvier et al (42) 51 
1 9 - 
2 75 - 
3 93 - 
Tawfik Zein et al (37) 73 
1 25 31 
2 57 85 
3 74 87 
Present study 192 
Low 23 57 
High 70 50 
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The specificity of voided and barbotage urine cytology were 92% and 95% 
respectively in the present study. Ten of the thirteen samples of voided urine 
cytology which was false positive were in patient whose primary tumour was 
T1G3 or multiple recurrence of T1G2 and had received BCG. Eight of the ten 
samples of barbotage urine cytology which was false positive were also patients 
with high grade primary tumour who had received BCG. The other five samples 
(two barbotage and three voided urine sample) which were false positive were in 
low grade tumors who had not received any form of intravesical chemotherapy. 
In a prospective study done by Kapila et al 73 the specificity of urine 
cytology was 87% for all grade tumours and it has ranged from 98-100%58 
depending on the grade of the tumour. 
Positive predictive value of voided urine cytology for TaG2/T1G2 tumours 
and T1G3/CIS tumours were 54% and 34% respectively. The negative predictive 
value of voided urine cytology for TaG2/T1G2 tumours and T1G3/CIS tumours 
were 96% and 98% respectively. 
Positive predictive value of barbotage urine cytology for TaG2/T1G2 
tumours and T1G3/CIS tumours were 54% and 33% respectively. The negative 
predictive value of barbotage urine cytology for TaG2/T1G2 tumours and 
T1G3/CIS tumours were 96% and 97% respectively. 
The positive predictive value (PPV) results too differ widely in different 
studies. The lowest of 13% was reported by Konety et al74 and Renshaw et al 31 
reported a positive predictive value 59% to 66%.   
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Several factors contribute to this poor ability of urine cytology to detect 
cancer cells: only a small sample of urine can be processed and only a fraction of 
the sample can be used for final analysis which reduces the chance of capturing 
tumor cells. Background cells such as erythrocytes and leukocytes also confound 
the cytologic technique 18. Furthermore, cytologic criteria that differentiate 
between low grade tumors and reactive cells can be ambiguous. In the follow up 
of bladder cancer, the low sensitivity of urine cytology limits its use as a detection 
tool. 
The Future of Cytologic Urinanalysis 
Improvements in Sample Preparation 
Efforts are underway to design faster, inexpensive and more sensitive 
point-of-care sample collection and preparation techniques that will significantly 
improve platforms on which routine and specialized urine cytopathologic tests are 
performed. The recent fabrication of a parylene membrane micro filter device that 
can capture circulating tumor cells from the blood of cancer patients by 
employing the principle of inherent differences in tumor cell size compared to 
normal blood cells 75 is also being evaluated for capture and characterization of 
exfoliated urothelial tumor cells from patient urine. The unique and precise 
engineering of the microfilter device allows enrichment of exfoliated tumor cells 
on a small surface area while eliminating background erythrocytes and 
leukocytes that typically confound routine urine cytologic specimens. This 
platform has shown promise in bladder cancer surveillance, and it is conceivable 
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that this can also be used for on-site bladder cancer detection protocols in the 
future. 
Automated Image Cytometry 
Abnormalities in DNA ploidy and nuclear shape are characteristic of tumor 
cells. While cytologists rely on identification of these changes in urine specimens, 
automated image analysis now allows identification of these changes on a more 
objective scale. The Quanticyt system employs image analysis to identify DNA 
ploidy abnormalities and nuclear morphometry 76. The karyometric system is 
based on two nuclear features: the 2c-deviation index (2cDI) and the mean of a 
nuclear shape feature, MPASS . Samples are scored as low, intermediate, or 
high-risk that has been determined by correlation with histology data. A study has 
shown that prediction of a cystoscopic lesion by routine cytology and Quanticyt 
was comparable, and the latter was superior for predicting tumor recurrence after 
normal findings at cystoscopy 77. Another group has employed artificial 
intelligence to develop a neural network-based digitized cell image diagnosis 
system that identifies potentially abnormal cells in bladder washes by algorithmic 
analysis 78. The selected digitized cell images are reanalyzed by two independent 
neural networks; one is trained to select single cancer cells and the other one 
cancer cell clusters, regardless of cell shape, overlapping, or staining. The 
selected cells or cell clusters are displayed on a high-resolution Computer screen 
for evaluation by a cytopathologist. The Quanticyt system has shown a sensitivity 
of 59%-69%, and specificity of 72.5%-93% in detecting bladder cancer 79, 80. It 
has also been suggested that employment of Quanticyt to analyze consecutive 
bladder washes can increase the detection rate of invasive disease in samples 
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that are labeled high-risk 81. In a pilot study, the neural network-based diagnosis 
system showed 92% sensitivity in diagnosing histologically confirmed tumors, as 
opposed to 69% for Quanticyt and 50% for routine cytology 78. While the major 
advantage of these cytometric analyses is label-free quantification that closely 
mimics the routine cytology procedure, a drawback is the need for a bladder 
wash sample instead of voided urine. 
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SUMMARY AND CONCLUSIONS 
Transitional cell carcinoma of the bladder is a common malignant 
neoplasm affecting both men and women.  Nonmuscle invasive TCC (about 70% 
of the affected population) is a chronic illness with no definite curative measures.  
However, patients with these tumors have excellent survival rate. Therefore, the 
main goal in their management is to diagnose the primary and recurrent tumors 
as early as possible and treat them.  
 Follow up cystoscopy is the gold standard for surveillance of this tumor.  
But it is expensive and invasive. The other non-invasive method is voided urine 
cytology which is less sensitive when compared with cystoscopy especially in 
picking up low stage, low grade lesions. And all the guidelines do recommend 
urine cytology during the follow up of all patients with nonmuscle invasive TCC. 
 Few studies21, 23, 25 have found the barbotage urine cytology to have better 
yield than voided urine cytology in the follow up of non-muscle invasive TCC 
bladder. Based on this background, we studied 192 patients with nonmuscle 
invasive TCC of the bladder in a prospective manner to assess the sensitivity of 
voided and barbotage urine cytology in the diagnosis of nonmuscle invasive TCC. 
We made the following observations.  
1. Out of 192 patients 172 were male and 20 were female, most of the 
patients were in their 4th or 6th decade of life.   
2. Initially, Of the 192 patients 82(42.70%) had pTa and 110(57.29%) had 
pT1 stage  
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3. The grade of the initial (primary) tumours were low grade in 120(62.5%) 
and high grade in 72(37.5%).  
4. For 192 patients, 250 review cystoscopies were done and 31(12.4%) had 
histologically proven recurrence.  
5. Among the recurrent tumors 16(51.61%) patients had pTa lesions 
13(41.93%) patients had pT1 tumours, 2(6.45%)patients had CIS 
6. Histological grade of the recurrent tumour was grade 2 in 21(67.74%) 
patients; grade 3 in 8 (25.8%) patients and CIS in 2 (6.45%) patients. 
7. Sensitivity of the barbotage urine cytology was 57% in low grade tumour 
when compared to voided urine cytology which was 23%. 
8. Sensitivity of the barbotage urine cytology was 50% in high grade           
tumour when compared to voided urine cytology which was 70%. 
9. Overall sensitivity, specificity, positive predictive value, negative predictive 
value of the voided urine cytology was 38.75%, 92%, 48% and 91% 
respectively. 
10. Overall sensitivity, specificity, positive predictive value, negative    
predictive value of the barbotage urine cytology was 54.83%, 95%, 62% 
and 93% respectively. 
11. Patients with positive urine cytology (voided or barbotage) but negative 
cystoscopy did not show TCC in the upper tract making these tests truly 
false positive. 
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Conclusion 
Cystoscopy, the current gold standard for bladder cancer detection, and 
follow up of TCC bladder exhibits high sensitivity and specificity will continue with 
its numero uno status. Urine cytology is an established method and there is 
sufficient evidence to show its high specificity. However the method suffers from 
low sensitivity.  
In the present study the sensitivity of 23% and 57% for the voided and barbotage 
urine cytology respectively strongly questions the need for these tests during the 
follow up. 
There would be no harm done if urine cytology is discontinued as a test for 
TCC bladder during the follow up of low grade nonmuscle invasive TCC.  
Barbotage urine cytology showed higher sensitivity than voided urine 
cytology, but was not significant enough to recommend for follow up of the TCC 
bladder. Also barbotage urine cytology is invasive and in it self can cause 
changes in the morphology of the cells68 affecting its sensitivity.  
In conclusion one could safely discontinue the protocol of urine cytology in 
the follow up of low grade TCC bladder as cystoscopy which is more sensitive is 
mandatory and is the standard of care during the follow up of TCC bladder. 
Barbotage urine cytology also showed poor sensitivity. In this study the 
barbotage urine cytology sensitivity (50%) was lower than the voided urine 
cytology (70%) for high grade tumours which was contrary to all the previous 
studies 21, 22, 23. Also it is an invasive test which can increase the morbidity by 
introducing infection and it is better if one can avoid this invasive test with poor 
sensitivity. 
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Informed consent document 
The Department of Urology at CMC, Vellore is conducting a study on voided 
urine and barbotage urine cytology in the patients with non muscle invasive TCC 
of bladder on follow up. 
It is a diagnostic test which involves giving a sample of voided urine for 
evaluation of malignant cells or any other abnormal cells. The barbotage sample 
is collected at the time of cystoscopy which will be done on all the patients on 
follow up for the TCC bladder. 
If you agree to participate in this study, the doctor will ask you to deposit one 
freshly voided urine sample in the cytology laboratory on the day planned for 
cystoscopy. The barbotage urine sample will be collected during the cystoscopy 
and will be sent to cytology laboratory by our staff. The results of these tests will 
be conveyed to you and the possible implications if any will be explained to you. 
Your decision not to participate in the study will not affect the care you will 
receive at the hospital in any way. Even if you do agree to become a study 
participant, you can withdraw from the study at any time without affecting the care 
that you will receive. The study is likely to expose you to urinary tract infection. 
The barbotage will not further increase the discomfort that occurs during the 
cystoscopy. 
There will be no immediate benefits from your participation in this study. This 
study will help us to determine the value of the cytology in follow up of TCC 
bladder. There will be no monetary compensation for this study, but the cost of 
this study will be born by the institute. 
The records concerning your participation are to be used only for the purpose of 
this research project. Any information obtained during this study will be strictly 
kept strictly confidential. Only members of the study team will have access to 
information. You can with draw from the study any time without affecting your 
present or future medical care at the hospital. 
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After the study the data will be analyzed, the results and the explanation of its 
implications will be published for everyone’s information. The identity of the 
participants will not be revealed. 
All study related queries and problems if any should be communicated to 
Dr.Srinivas, Registrar, Department of urology, CMC, Vellore, Tamil Nadu. 
Telephone – 0416 2282111 
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INFORMED CONSENT 
  Study Title: PROSPECTIVE ANALYSIS OF VOIDED AND BARBOTAGE URINE  
                             CYTOLOGY IN THE ROUTINE FOLLOW UP OF NON-MUSCLE  
                            INVASIVE TRANSITIONAL CELL CARCINOMA OF BLADDER           
 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
 
(i) I confirm that I have read and understood the information sheet dated 
_________ for the above study and have had the opportunity to ask questions. [ ] 
 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. [ ] 
 
 (iii) I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [ ] 
 
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) [ ] 
 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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PROFORMA 
 
Name: 
Age: 
Sex: 
Hospital number: 
Address: 
Phone number: 
Date of first resection: 
Histopathology: 
 
       First biopsy: Lesion 
                            pT stage  
                            Grade 
 
Immediate post-op intravesical chemotherapy: 
 
Induction/maintenance BCG: 
 
Number of recurrence: 
 
Follow up since(months): 
 
Investigations during the study: 
 
            Biochemistry:   Urine microscopy Manual: 
                                      Urine culture and sensitivity: 
                                      Serum creatinine: 
 
IVU if done during the study: 
USG if done during the study: 
CT if done during the study: 
 
Cytology; 
1. Voided urine cytology 
2. Barbotage urine cytology 
 
Cystoscopy findings: 
                                  1. Anatomy of urethra and bladder 
                                  2. Tumour – number 
                                                      Size 
                                                      Sessile/papillary/evidence of CIS 
 
Histopathology of the recurrent tumour: 
                                                                Lesion 
                                                                pT stage 
                                                                Grade 
 
 
 
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
1 sadan chakrabarty 590216d 64 1 30.4.09 pap.2x3.rt.lat 1 0 0
2 sadan chakravarthy 590216d 65 1 30.4.09 pap.2x3.rt.lat 1 0 0
3 atul chandra maity 533379d 58 1 10.9.09 pap0.5x0.5lat.dome 0 1 0
4 atul chandr maity 533379d 57 1 2005 papillary 0 1 0
5 pradip das 458110d 44 1 2.07.09 sessile.1x1 post wall 1 0 1
6 pradip das 458110d 44 1 2.07.09 preop cytology + 1 0
7 budhan kahar 930779b 55 1 2000 papillary 2x2.post wall 1 0 0
8 netai das 551785d 58 1 may.07 papillary 1 0 1
9 netai das 551785d 58 1 may.07 papillary 1 0 1
10 tharmaraj 946591c 63 1 9.11.07 papillary 1 0 0
11 namita dangar 520088d 27 0 20.08.09 papillary 1 0 0
12 hari pada sarkar 469775c 60 1 28.5.04 papillary 1 0 1
13 afzal 416439d 31 1 17.3.09 papillary 1 0 1
14 arun kumar sarkar 605959d 51 1 24.12.09 pap.4x3.rt.u.o 1 0 0
15 Md.Farooque sahab 404669d 61 1 18.2.09 pap2x2.lt.lat.ant 0 1 0
16 uttam 801420c 54 1 6.5.06 pap.1x1.rt.u.o 1 0 0
17 shiv nath prasad 144365d 68 1 13.2.08 papillary,postwall,dome 0 1 0
18 shiv nath prasad 144365d 68 1 13.2.08 papillary,postwall,dome 0 1 0
19 gargee hazra 541317d 39 0 23.9.09 papillary2x2,postwall 1 0 0
20 gargee hazra 541317d 39 0 23.9.09 papillary2x2,postwall 1 0 0
21 sushil kumar singh 636053c 44 1 20.5.05 pap.3x3.rt.lat 1 0 0
22 arokia das 252247d 60 1 17.12.08 papillary 0 1 0
23 arokyadas 252247d 41 1 16.12.08 pap.sesile.1.5x1..5rt.lat 0 1 0
24 arokyadas 252247d 62 1 16.12.08 pap.sesile.1.5x1..5rt.lat 0 1 0
25 sisir mukerjee 527627d 56 1 1.9.09 pap.3x3.rt.lat.post 0 1 0
26 shambu nath prasad 144365d 56 1 12.12.07 pap.2x1.5.rt.u.o 1 0 0
27 shambu nath prasad 144365d 56 1 12.12.07 pap.2x1.5.rt.u.o 1 0 0
28 Md.farooque sahab 404669d 62 1 18.2 09 papillary,left lat.wall.ant wall.2x2cms 0 1 0
29 ramalingam 394876d 41 1 16.2.09 papillary4x3 rt.lat wall 1 0 0
30 ramalingam 394876d 41 1 16.2.09 papillary4x3 rt.lat wall 1 0 0
31 tarun kumar banerjee 947216c 58 1 21.12.06 pap.0.2x0.5.dome.rtt.u.o 0 1 0
32 abdul aziz 627109d 60 1 21.12.06 outside 0 1 0
33 moshraf ali 747464c 54 1 2.1.06 pap.3x3.lt.lat 1 0 0
34 natarajan 252545d 77 1 13.6.08 papillary,0.5x2,post,dome 0 1 0
35 ramchandra prasad singh 762204c 69 1 17.1.06 scar tsissue lat wall 1 0 0
36 sujit samada 399701d 39 1 10.2.09 papillary,3x2,rt.lat wall 1 0 0
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
37 abdul khalaque 620801d 76 1 apr.2009 papillary,3x2,rt.lat wall 1 0 0
38 kumar.t 486999b 58 1 26.3.07 papillary 0.8,trigone 1 0 0
39 gadadhar mondal 634492c 59 1 23.10.09 excision with blader cuff on 23.10.09 1 0 1
40 kumar 486999b 59 1 2001 pap1x1.post 0 1 0
41 kumar 486999b 59 1 2001 pap1x1.post 0 1 0
42 mriganka shankar giri 263996d 62 1 30.6.08 pap.2x0.5.dome.ant 0 1 0
43 md hashim 627739d 56 1 30.12.09 pap.2x2.rt.lat 1 0 0
44 haripada dasguta 759418b 77 1 10.9.02 pap.0.2x0.2.rt.u.o.post 0 1 0
45 haripada dasguta 759418b 77 1 10.9.02 pap.0.2x0.2.rt.u.o.post 0 1 0
46 kajal dey 699045c 49 0 20.9.05 papillary 2x2 dome.multiple recirrence 1 0 0
47 tarun kumar banerjee 947216c 60 1 22.12.06 pappilary2x2 1 0 0
48 khirod kumar mandal 274699d 43 1 28.7.08 sessile.3x2 above rt.u.o 1 0 0
49 kanakamma 502204b 57 0 2000 sessile.3x2 above rt.u.o 0 1 0
50 madhu sudhan roy 403199c 55 1 20.9.05 pap.0.7.0.3.dome 1 0 0
51 naba kumar goswami 913594b 45 1 30.6.04 pap.1x1.5.lt.u..o 1 0 0
52 gowrammal 599400c 60 0 10.3.2005 papilary1.5x1.postwall 1 0 0
53 quershi 385279d 72 1 10.2.09 papillaary3x3.rt.lat wall 1 0 0
54 kankkamma 502204b 55 0 27.11.00 pap.0.7.0.3.dome 1 0 0
55 ashok kumar yadav 766767c 38 1 8.2.06 pap.1x1.5.lt.u..o 1 0 0
56 moshraf ali 747464c 53 1 14.12.06 pap.3x3.lt.lat 1 0 0
57 musharraf hussain talukdar 506795d 63 1 20.4.08 pap.3x2.dome.rt.lat 0 1 0
58 musharraf hussain talukdar 506795d 63 1 20.4.08 pap.3x2.dome.rt.lat 0 1 0
59 bhulu mitra 964496b 54 1 21.4.06 papillary 1x0.5.above rt.u.o 1 0 0
60 celina ranee 410965d 64 0 26.2..09 papillary 2x1 lt.lat wal 1 0 0
61 md.saifuddin 334080c 43 1 24.7.03 papillary 1x2.dome.postwall 0 1 0
62 gowrammal 599400c 65 0 7.1.05 pap.1.5x1.rt.lat 1 0 0
63 narayan pillai 771540c 67 1 17.2.03 pap.3x3.ant.1x1.lt.lat 0 1 0
64 narayan pillai 771540c 67 1 17.2.03 pap.3x3.ant.1x1.lt.lat 0 1 0
65 narayan pillai 771540c 67 1 17.2.03 pap.3x3.ant.1x1.lt.lat 0 1 0
66 md.saifuddin 334080c 55 1 24.7.03 pap.2x3.dome 0 1 0
67 niranjan biswas 123479d 69 1 18.3.10 pap.2x2.post 1 0 0
68 niranjan biswas 123479d 69 1 18.3.10 pap.2x2.post 1 0 0
69 niranjan biswas 123479d 69 1 18.3.10 pap.2x2.post 1 0 0
70 krishn pada biswas 581563d 55 1 16.11.09 papillary 0.5x0.5.trigone 1 0 0
71 krishn pada biswas 581563d 55 1 16.11.09 papillary 0.5x0.5.trigone 1 0 0
72 krishn pada biswas 581563d 55 1 16.11.09 papillary 0.5x0.5.trigone 1 0 0
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
73 sarojamma 565328d 65 0 13.11.09 papillaary3x3.lt.lat wall 1 0 0
74 sarojamma 565328d 65 0 13.11.09 papillaary3x3.lt.lat wall 1 0 0
75 gad dhar roy 430124d 67 1 24.3.09 sess.2x2.rt.lat 1 0 0
76 gad dhar roy 430124d 55 1 24.3.09 sess.2x2.rt.lat 1 0 0
77 naarayan pillai 7715540c 67 1 17.2.06 pappilary,lat ant,wall,circumferentially neck 0 1 0
78 naarayan pillai 7715540c 67 1 17.2.06 pappilary,lat ant,wall,circumferentially neck 0 1 0
79 pollu yasodamma 500284d 55 0 30.09.09 papillary1x0.5.lt.lat.post wall 0 1 0
80 gadadhar roy 430124d 54 1 24.3.09 sessile2x2.lt.lat.wall 1 0 0
81 gadadhar roy 430124d 54 1 24.3.09 sessile2x2.lt.lat.wall 1 0 0
82 shaji john 629147c 36 1 13.5.05 pap.1x2.rt.lat 1 0 0
83 ramanathan 411797c 81 1 21.9.05 pap.3x3 1 0 0
84 ram prabodh singh 050203d 53 1 22.6.07 papillary1x1 lt.latwall 0 1 0
85 ram prabodh singh 050203d 53 1 22.6.07 papillary1x1 lt.latwall 0 1 0
86 vengojammal 949763c 60 0 3.4.07 papillary.2x3.rt.lat wall 0 1 0
87 vengojammal 949763c 60 0 3.4.07 papillary.2x3.rt.lat wall 0 1 0
88 brundaban mohanty 865948c 49 1 2.8.06 papilary.1x3.rt.lat 0 1 0
89 amar ghosh 449729d 55 1 1.5.09 pap.multiple thro.out UB.turt.twice 0 1 0
90 amar ghosh 449729d 55 1 1.5.09 pap.multiple thro.out UB.turt.twice 0 1 0
91 amar ghosh 449729d 56 1 1.5.09 papillary thr out UB 0 1 0
92 amar ghosh 449729d 56 1 1.5.09 papillary thr out UB 0 1 0
93 uday kumar 34 865389c 34 1 7.8.06 papillary 1 0 0
94 uday kumar 34 865389c 34 1 7.8.06 papillary 1 0 0
95 uday kumar 34 865389c 34 1 7.8.06 papillary 1 0 0
96 dibakar das 515811d 37 1 7.8.09 pap.0.5x0.5.lt.lat 0 1 1
97 dibakar das 515811d 37 1 7.8.09 pap.0.5x0.5.lt.lat 0 1 1
98 dibakar das 515811d 37 1 7.8.09 pap.0.5x0.5.lt.lat 0 1 1
99 muthu 576366d 68 1 14.12.09 pap.2x3.rt.lat 1 0 0
100 muthu 576366d 68 1 14.12.09 pap.2x3.rt.lat 1 0 0
101 paltu sardar 190882d 49 1 26.2.08 pap.2x3.rt.lat 1 0 0
102 ashok kumar tripathy 271382d 49 1 26.2.08 pap.2x2.rt.u.o 1 0 0
103 ashok kumar tripathy 271382d 49 1 26.2.08 pap.2x2.rt.u.o 1 0 0
104 ashok kumar tripathy 271382d 49 1 14.5.10 pap.2x2.rt.u.o 1 0 0
105 ismail 653399d 64 1 14.5.10 mul.pap.sessile.thr.out u.b 0 1 1
106 sivanthi adithan 211649d 62 1 1.4.08 pap.6x6.dome 1 0 1
107 sambu nath datta 687443d 49 1 11.5.10 pap.2.5.2.rt.lat 1 0 0
108 sambu nath datta 687443d 49 1 11.5.10 pap.2.5.2.rt.lat 1 0 0
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
109 rabindranath dhar 717716d 42 1 2009 pap.2.5.2.rt.lat 1 0 0
110 jesudas jabamani 048635d 66 1 3.7.07 pap.1x1.5.rt.lat 1 0 0
111 jesudas jabamani 048635d 66 1 3.7.07 pap.1x1.5.rt.lat 1 0 0
112 jesudas jabamani 048635d 66 1 3.7.07 pap.1x1.5.rt.lat 1 0 0
113 kasinath das 480873d 46 1 may.09 papillary 0.5x0.5.lt.lat 1 0 0
114 dilip saha 598805d 49 1 28.12.09 pap.1.5.2.rt.lat 1 0 0
115 asim banerjee 718667d 47 1 2.7.10 ses.4x3.dome.lt.lat 1 0 1
116 gowri shankar gayal 569640c 55 1 2.7.10 papillary 0.5x0.5.lt.lat 1 0 0
117 joseph athisayam 469469c 70 1 12.5.04 papillary 0.5x0.5.lt.lat 1 0 0
118 subramaniam 690289d 49 1 14.5.10 pap.3x3.lt.lat 1 0 0
119 subramaniam 690289d 49 1 14.5.10 pap.3x3.lt.lat 1 0 0
120 pratima das 805929d 47 0 2.7.10 pap.1x0.5.ant &rt.lat 0 1 0
121 mridul chandr roy 776616c 24 1 1.3.06 pap2x1.5.rt.lat 1 0 0
122 biplab ray 419019c 62 1 9.2.04 pap.4x2.ant.wall 1 0 0
123 durai pandi 427956d 48 1 19.3.09 pap.1x0.5.ant &rt.lat 0 1 0
124 durai pandi 427956d 48 1 2.7.10 pap.1x0.5.ant &rt.lat 0 1 0
125 durai pandi 427956d 48 2.7.10 pap.1x0.5.ant &rt.lat 0 1 0
126 amulya chandra mandal 569750d 64 1 17.11.2009 pap.1x1.5.lt.u..o 1 0 0
127 amulya chandra mandal 569750d 64 1 17.11.2009 pap.1x1.5.lt.u..o 1 0 0
128 amulya chandra mandal 569750d 64 1 17.11.2009 pap.1x1.5.lt.u..o 1 0 0
129 sunil kumar panda 198145d 36 1 26.3.08 papillary3x2.above rt.ur.orifice 1 0 0
130 ram nandan mandal 939089c 46 1 28.11.06 rt.lat.outside 1 0 0
131 niresh kundu 111159c 36 1 2003 ?pap.3x3.rt.lat 1 0 0
132 gandhi 918446c 58 1 24.11.09 papillary 3x3 lt.latwall 1 0 0
133 sukumar duta 399638c 67 1 18.11.08 pap.2x3.rt.lat 1 0 0
134 sukumar duta 399638c 67 1 18.11.08 pap.2x3.rt.lat 1 0 0
135 laxmi 494365c 58 0 5.6.09 pap.4 tumor.4x4.rt.lat+1x1 0 1 0
136 laxmi 494365c 58 0 15.6.09 pap.4 tumor.4x4.rt.lat+1x1 0 1 0
137 laxmi 494365c 58 0 5.6.09 pap.4 tumor.4x4.rt.lat+1x1 0 1 0
138 joseph 423031c 74 1 13.2.04 pap.4x2.rt.lat 0 0 0
139 manickiam 447798d 40 1 6.5.09 pap.5x4.lt.lat.uo.+wall 1 0 0
140 jamaluudin 626310d 64 1 2.2.10 papilary3x3,rt.lat wall 1 0 0
141 sk.jamaluddin 626310d 63 1 2.2.10 papilary3x3,rt.lat wall 1 0 0
142 sk.jamaluddin 140501a 44 1 26.11.07 papilary3x3,rt.lat wall 1 0 0
143 sk.jamaluddin 140501a 44 1 26.11.07 papilary3x3,rt.lat wall 1 0 0
144 jitendra kumar tak 183938d 56 1 19.2.08 sessile.1x1 post wall 1 0 0
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
145 shashanka sekar mandal 656861d 60 1 29.3.10 pap.2x3.rt.lat 1 0 0
146 madhusudhan biswas 014223d 62 1 1.5.07 pap.3x3.lt.lat 1 0 0
147 mathew 647862d 59 1 15.1.10 pap.3x3.lt.lat 1 0 1
148 ajit kumar bera 309277d 73 1 8.09.08 sessile.1x1 post wall 1 0 0
149 panniyapan 806297b 62 1 2003 pap.multiple 0 1 0
150 gour gopal jana 621204c 45 1 0.11.04 pap.2x3.rt.lat 1 0 0
151 subramaniam 368249d 68 1 28.12 .09 papillary.3x3.0.5x0.5.dome .ant.lat wall 0 1 0
152 subramaniam 368249d 68 1 28.12 .09 papillary.3x3.0.5x0.5.dome .ant.lat wall 0 1 0
153 kirid kumar mandal 274699d 44 1 28.1.08 pap3x2.r.lat 1 0 0
154 santa saha 607173d 43 1 28.12 .09 pap.4x4. 1 0 0
155 santa saha 607173d 43 1 28.12.09 pap.4x4. 1 0 0
156 jaganath maity 169611b 63 1 ?2003 sessile.1x1 post wall 1 0 0
157 kali pada patra 656425d 73 1 27.3.10 pap.multiple 0 1 0
158 sankar dutta 746942d 55 1 23.6.10 pap.2x1.rt.lat 1 0 0
159 sankar dutta 746942d 55 1 23.6.10 pap.2x1.rt.lat 1 0 0
160 pradip das 458110d 1 2.07.09 sessile.1x1 post wall 1 0 1
161 pradip das 458110d 44 1 2.07.09 sessile.1x1 post wall 1 0 1
162 rajesh arora 118427c 64 1 24.1.02 pap.multiple 0.2 0 1 0
163 subhas chatrejee 333737c 61 1 8.1.07 pap.rt.lt.ant.wall 0 1 0
164 samir saha 722194d 46 1 24.6.10 pap.3x2.lt.lat 1 0 0
165 mohamed jainul 645019d 50 1 24.3.06 sess.0.5x0.5.post wall 1 0 0
166 mohamed jainul 645019d 50 1 24.3.06 sess.0.5x0.5.post wall 1 0 0
167 pushpa dey 199052d 60 0 13.3.08 pap.0.5x0.5rt.u.o 1 0 0
168 atul chandr maity 533379d 58 1 2005 pap.2x3,1x1.lt.u.o 0 1 0
169 nakul mitr 430764c 32 1 26.2.04 pap.5x3.rt.lat 1 0 0
170 kali prasad saha 772692d 62 1 24.9.10 pap.0.5x0.5rt.u.o 1 0 0
171 ganesan 754122d 54 1 13.7.04 pap.0.5x0.5rt.u.o 1 0 0
172 jayanthi basak 620668d 30 0 31.1.10 papillary2x2,postwall,lat wall 0 1 0
173 ismail 705947d 63 1 1.6.10 pap.1.5x1.rt.lat 1 0 0
174 ismail 705947d 1 1.6.10 pap.1.5x1.rt.lat 1 0 0
175 sanath kumar mukerjee 728158c 72 1 1711.05 pap.2.5x2.5.rt.u.o 1 0 0
176 sija grewal 523311d 34 0 26.8.09 pap.0.5x0.5rt.u.o 1 0 0
177 purna chandra madhani 720085d 51 1 7.7.10 pap.2x3,1x1.lt.u.o 0 1 0
178 ashok kumar ray 946952b 59 1 1999 pap.1.5x1.rt.lat 1 0 0
179 anukul das 753565b 60 1 6.5.1999. 4tumor.2x2.1x2.3x2 0 1 0
180 sudhangshu kumar roy 642739d 63 1 7.3.10 pap.2x3,rt..u.o 1 0 0
sno. Name Hosp.No. Age in yrs Sex
year of diagnosis 
primary tumor
primary tumor 
characteristics single multiple CIS
181 dharmaraj 946591c 66 1 9.11.07 pap.cis.3x2.rt.lt.post 0 1 1
182 naresh prasad gupta 517246b 63 1 2003 pap.cis.3x2.rt.lt.post 0 1 1
183 dilip rambabu 348575b 53 1 27.3.07 pap.3x3.lt.u.o 1 0 0
184 shardammal 113882d 76 0 3.1.08 pap.0.5x0.5rt.lat 0 1 0
185 muni krishna 692124d 70 1 20.5.10 pap.3x2.trigone.post 0 1 0
186 chitranjan gowsami 377537d 63 1 23.12.08 papillary3x3postwall 1 0 1
187 lalitha alexander 736811d 75 0 16.8.07 sess.0.3x0.3.post 0 1 0
188 surendra nath chuan 264254c 62 1 2003 pap.sesile.1.5x1..5rt.lat 0 1 0
189 md.atul.haque 683875d 69 1 24.5.10 pap.1.5x1.5.rt.lat 1 0 0
190 niranjan biswas 123479d 69 1 18.3.10 pap.2x2.post 1 0 0
191 suniti ghosh 473294d 52 0 11.6.09 pap.1.5x1.rt.lat 1 0 0
192 anil chandra ray 337187d 59 1 18.11.08 pap.sessile thro.out.UB.resected twice 0 0 0
193 anil chandra ray 337187d 59 1 18.11.08 pap.sessile thro.out.UB.resected twice 0 0 0
194 saheb ali 141024d 64 1 20.11.07 sess4x3.lt.lat 1 0 0
195 nilakanta das 319349d 49 1 25.09.08 pap.sessile thro.out.UB.resected twice 0 0 0
196 katahu ram 700672d 73 1 28.5.10 pap4x4.lt.lat.post 0 1 0
197 dilwar rehman 561363d 66 1 23.10.09 pappilary & sessile,rt.lat,post wall,neck 0 1 0
198 nimai hansda 714359d 48 1 18.6.10 pap2x2.lt.lat 1 0 0
199 md.sahajahan 819594d 52 1 1.22003 pap.2x3 1 0 0
200 bijoy patra 218678d 56 1 20.8.07 pap.4x3.lt.lat.post 1 0 0
201 nani gopal chowdhary 310527d 62 1 24.2.09 papillary.1.5x1.5.rt.u.o.lat.wall 0 1 0
202 sauktiya kamin 483563d 50 1 20.08.10 pap2x2.lt.lat 1 0 0
203 hari pada das gupta 759418b 57 1 19.12.06 pappilary 0 1 0
204 ramesh chandra kalita 377384d 57 1 26.12.08 pap.3x3.lt.lat 0 1 0
205 madhu sudhan roy 403199c 71 1 26.12.08 pappilary 0 1 0
206 ramalingam 394876d 42 1 19.12.06 sess4x3.lt.lat 1 0 0
207 sivanthi adithan 211649d 63 1 3.4.08 pap.6x6.dome.biman.pal 1 0 1
208 md.fazlul kabir 710687d 52 1 13.3.10 ?pap.3x2.rt.lat 1 0 0
209 basudeb adhikary 755613d 52 1 20.08.10 pap2x2.lt.lat 1 0 0
210 basudeb adhikary 755613d 52 1 20.08.10 pap2x2.lt.lat 1 0 0
211 asim bhandopadhyay 718667d 48 1 2.7.10 sess4x3.lt.lat 1 0 0
212 samir battacharya 773306d 52 1 7.9.10 pap2x2 lt.lat 1 0 0
213 kamal kanti ghosh 946544c 68 1 19.12.06 pappilary 0 1 0
214 Md.Azimuddin Ansari 617803d 64 1 21.1.10 pap.2x3.rt.u.o 1 0 0
215 krishnaiah 668861d 54 1 18.5.10. pap5x5.lt.lat.ant 0 1 0
216 jolly mathew 310866d 45 0 26.8.08 pap.1.5x1.rt.u.o.post 0 1 0
sno. Name Hosp.No. Age in yrs Sex
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217 nedunchezian 140501a 42 1 20.11.07 pap3x1.rt.lat 1 0 0
218 devaraj 978070c 44 1 10 .10.07 pap3x1.rt.lat 1 0 0
219 phatik banerjee 949322b 54 1 10.9.09 pap1x1.dome.lt.lat 0 1 0
220 madhab chandra bhandary 421170d 55 1 10.12.08 pap3x1.lt.lat 0 1 0
221 murugesan 684824d 59 1 11.4.10, pap.2x2.dome.lt.lat.post.neck 0 1 0
222 bijay kumar sarkar 743720c 51 1 2003 pap.1x0.5.ant &rt.lat 0 1 0
223 pradeep kumar chowdhary 233888d 52 1 12.5.08 pap.2x3.rt.lay 1 0 0
224 mukhlal prasad gupta 053077d 64 1 5.7.07 pap.2x2.1x1.rt & lt.lat 0 1 0
225 mathew 647862d 53 1 12.1.10 pap.2x3.rt.&.lt.lat 0 1 1
226 sasanka sekar mandal 656861d 35 1 29.3.10 pap.3x2.5.neck 1 0 0
227 shankar kumar pal 434619d 64 1 6.4.09 pap.2x2.1x1.rt & lt.lat 0 1 0
228 bhubaneswar roy 746364d 35 1 2008 pap.2x2.1x1.rt & lt.lat 0 1 0
229 sudangshu kumar roy 642739d 63 1 12.3.10 pap.2x2.lt.u.o 1 0 0
230 basudeb dahikary 755613d 52 1 20.8.10 pap.2x2.lt.lat 1 0 0
231 anukul das 753565b 60 1 6.5.10 pap.3x2.rt.lat 1 0 0
232 quershi 385279d 72 1 19.12.06 pap.lt.alt&ant.neck 0 1 0
233 quershi 385279d 72 1 19.12.06 pap.lt.alt&ant.neck 0 1 0
234 madhab chandra bhandary 421170d 56 1 10.12.08 sessile 2x2.lt.lat wall 1 0 0
235 md.sharifulislam 361976d 46 1 28.11.08 pap.1x2.rt.lat 1 0 0
236 nirmal kumar jain 143897c 56 1 1.4.03 pap.lt.alt&ant.neck 0 1 0
237 sukumar duta 356886d 59 1 18.11.08 pap.3x3.lt.lat 0 1 0
238 narayan chandra das 317901b 60 1 2001 pappilary & sessile,rt.lat,post wall,neck 0 1 0
239 dilip kumar mondal 757899c 50 1 10.3.06 pap2.5x2.5.above rt.u.o 1 0 0
240 asit das 748175c 47 1 23.12.05 pap.1x2.rt.lat.narrow stalk 1 0 0
241 abrar ali 184646d 58 1 19.2.08 pap.1x2.rt.u.o 1 0 0
242 nitya ranjan mondal 246628C 57 1 1998 4papgrowth.4x5 1 0 0
243 nitya ranjan mondal 246628C 57 1 1998 4papgrowth.4x5 1 0 0
244 sankar kumar pal 434619d 63 1 6.4.09 pap.1x2.rt.lat 1 0 0
245 krishnaiah 668861d 56 1 18.5.10 pap.rt.lat+ant.5x4 1 0 0
246 partha pratim ghosal 047819d 50 1 29.6.07 pap.2x2 lt.lat 1 0 0
247 dilwar rehman 561363d 66 1 23.10.09 pappilary & sessile,rt.lat,post wall,neck 0 1 0
248 vasantha kumari 148029d 35 0 23.2.10 pap.2x2 lt.u.o 1 0 0
249 narayan chandra ganai 128486d 45 1 2.7.10 pap.3x2.rt.lat 1 0 0
250 sushil kumar singh 636053c 45 1 20.5.05 pap.rt.lat+ant.5x4 1 0 0
sno. primary tumor stage/grade
intravesical 
chemotherapy BCG
Date of 
follow up
recurrent tumor 
stage/grade
voided urine 
cytology
Barbotage 
urine cytology cystoscopy
UTI present 
study
1 tag2 1 0 30.11.09 0 0 0 0 0
2 tag2 1 0 24.9.10 0 0 0 0 0
3 tag2 1 0 21.12.09 0 2 0 0 0
4 tag2 1 1 18.12.09 1 0 0 0 0
5 t1g3 0 1 18.05.10 0 0 0 0 0
6 t1g3 0 1 27.06.09 tig2 0 0 1 0
7 tag2 1 0 16.8.09 tag2 1 1 1 0
8 tag2 0 0 31.12.09 0 0 0 0 0
9 tag2 0 0 17.6.10 0 0 0 0 0
10 t1g3 0 1 14.12.09 0 0 0 0 0
11 tag2 0 0 26.12.09 0 0 0 0 0
12 t1g2 0 0 29.12.09 0 0 0 0 0
13 tag2 0 0 30.12.09 0 0 0 0 0
14 t1g3 1 0 1.1.10 t1g3 1 1 1 0
15 tag2 1 0 12.1.10 tag2 1 1 1 0
16 t1g2 1 0 13.1.10 0 0 1 0 1
17 t1g3 1 1 13.1.10: 0 1 1 0 1
18 t1g3 1 1 18.9.10 0 0 0 0 0
19 tag2 1 0 13.1.10 0 0 0 0 0
20 tag2 1 0 16.8.10 0 0 2 0 0
21 t1g3 1 1 21.1.10 0 0 0 0 0
22 tag2 1 0 13.1.10 tag2 0 0 1 0
23 tag2 1 0 12.7.10 0 0 0 0 0
24 tag2 1 0 7.10.10 0 0 0 0 0
25 t1g3 1 0 27.1.10 0 1 2 0 0
26 t1g3 1 1 14.1.10 tig2 1 0 1 0
27 t1g3 1 0 16.9.10 0 0 0 0 0
28 tag2 1 0 12.01.10 tag2 1 1 1 0
29 tag2 1 0 15.1.10 0 0 0 0 0
30 tag2 1 0 30.4.10 0 0 0 0 0
31 tag2 1 0 18.2.10 0 0 0 0 0
32 t1g1 1 0 29.1.10 0 0 0 0 0
33 t1g2 1 1 8.2.10 0 0 0 0 0
34 t1g3 1 1 21.1.10 0 0 0 0 0
35 t1g3 1 1 28.1.10 0 0 0 0 0
36 tag2 1 0 28.1.10 0 0 0 0 0
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37 tag2 1 0 1.2.10 0 1 1 0 0
38 tag2 0 0 5.2.10 0 0 0 0 0
39 tig3 cis 0 1 8.2.10 cis 1 1 1 1
40 tag1 1 0 14.1.11 0 0 0 0 0
41 tag1 1 0 5.2.10 0 0 0 0 0
42 tag2 1 0 16.4.10 0 0 0 0 0
43 t1g2 1 0 1.2.10 0 1 1 1 0
44 tag2 1 0 22.3.10 tag2 1 1 1 0
45 tag2 1 0 26.11.10 tag2 0 1 1 0
46 t1g2 1 1 15.2.10 0 0 0 0 0
47 tag2 0 1 18.2.10 0 0 0 0 1
48 t1g3 1 1 19.2.10 0 0 0 0 1
49 tig3 0 1 23.2.10 0 0 0 0 1
50 tag2 1 0 24.2.10 0 0 0 0 0
51 t1g2 0 0 24.2.10 0 0 0 0 0
52 t1g2 0 0 25.2.10 tag2 0 1 1 0
53 tag2 0 0 18.2.10 0 0 1 0 0
54 t1g2 1 0 17.2.10 0 2 0 0 0
55 t1g2 1 0 8.5.10 0 0 0 0 0
56 t1g2 1 1 8.2.10 0 0 0 0 0
57 tag1 1 0 1.2.10 0 0 0 0 0
58 tag1 1 0 21.8.10 0 0 1 0 0
59 t1g2 1 0 25.2.10 tag2 0 1 1 0
60 tag2 1 0 26.2.10 0 0 0 0 0
61 tag3 1 0 4.3.10 0 0 0 0 0
62 t1g2 1 0 3.3.10 tag2 0 1 1 0
63 t1g2 0 0 11.1.11 t1g3 1 0 1 0
64 t1g2 0 0 8.7.10 0 1 1 0 0
65 t1g2 1 1 18.3.10 0 0 0 0 0
66 t1g3 1 0 4.3.10 0 0 0 0 0
67 tag2 1 0 13.1.11 0 0 0 0 0
68 tag2 1 0 24.6.10 0 0 1 0 0
69 tag2 1 0 18.3.10 tag2 0 0 1 0
70 t1g2 1 0 4.3.10 0 0 0 0 0
71 t1g2 1 0 18.6.10. 0 0 0 0 0
72 t1g2 1 0 22.11.10 0 0 0 0 0
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73 t1g2 1 1 1.3.10 0 0 0 0 0
74 tag2 0 0 17.6.10 0 0 0 0 0
75 t1g3 0 1 9.9.10 0 0 0 0 0
76 t1g3 1 1 8.3.10 0 0 0 0 0
77 t1g2 1 1 18.3.10 0 0 0 0 0
78 t1g2 1 0 8.7.10 0 1 0 0 0
79 t1g3 1 0 5.3.10 t1g3 1 0 1 1
80 t1g3 1 1 5.3.10 0 0 0 0 0
81 t1g3 1 1 9.9.10 0 0 0 0 0
82 t1g3 0 1 29.3.10 0 0 0 0 0
83 t1g2 0 0 29.3.10 0 0 0 0 1
84 t1g1 1 0 9.3.10 0 0 0 0 0
85 t1g1 1 0 17.8.10 0 0 0 0 0
86 t1g2 1 0 23.3.10 0 0 0 0 0
87 t1g2 1 0 22.10.10 0 0 0 0 0
88 tag2 1 0 23.3.10 0 0 0 0 0
89 t1g3 0 1 25.3.10 0 0 0 0 0
90 t1g3 0 1 24.6.10, 0 0 0 0 0
91 t1g3 1 1 29.11.10 chr cyst 0 0 1 0
92 t1g3 1 1 10.12.09 0 0 0 0 0
93 t1g2 0 0 25.3.10 0 0 0 0 0
94 t1g2 0 0 12.7.10, 0 0 0 0 0
95 t1g2 0 0 12.10.10 0 0 0 0 0
96 t1g3 0 1 26.3.10 0 1 0 0 0
97 t1g3 0 1 31.7.10 0 0 0 0 0
98 t1g3 0 1 7.12.10 0 0 0 0 0
99 t1g2 1 0 20.8.10 0 0 0 0 0
100 t1g2 1 0 20.3.10 0 0 0 0 0
101 t1g3 1 1 21.10.10 0 0 0 0 0
102 t1g3 1 1 12.1.11 t1g2 0 0 1 0
103 t1g3 1 1 18.9.10 0 0 0 0 0
104 t1g3 1 1 14.6.10 0 1 0 0 0
105 t1g3 0 1 15.6.10 bcg cystitis 1 0 1 0
106 t1g3 1 1 18.6.10 tig3 0 1 1 0
107 t1g3 1 1 22.6.10 0 0 1 0 0
108 t1g3 1 1 26.11.10 0 0 0 0 0
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109 tag2 1 0 21.6.10 0 0 0 0 0
110 t1g3 1 1 24.6.10 0 2 0 0 0
111 t1g3 1 1 27.12.10 0 0 0 0 0
112 t1g3 1 1 10.1.11 0 0 0 0 0
113 t1g3 1 1 20.6.10 tag2 0 1 1 0
114 tag2 1 0 29.6.10 0 0 0 0 0
115 cis 0 1 23.112.10 0 0 0 0 0
116 t1g2 1 0 14.6.10 0 0 0 0 0
117 t1g2 0 0 17.6.10 0 0 0 0 0
118 t1g3 1 bcg 2.7.10. chr cyst 0 1 1 0
119 t1g3 1 1 8.10.10 0 0 0 0 0
120 t1g2 1 0 21.10.10 0 0 0 0 0
121 tag2 1 0 9.7.10 0 0 0 0 0
122 t1g2 0 1 9.7.10 0 0 0 0 0
123 t1g3 1 1 12.7.10 0 0 0 0 0
124 t1g3 1 1 7.10.10 0 0 0 0 0
125 t1g3 1 1 7.1.11 0 0 0 0 0
126 tag2 1 0 16.3.10 0 0 0 0 0
127 tag2 1 0 29.11.10 0 0 0 0 0
128 tag2 1 0 24.6.10 0 1 1 0 0
129 t1g3 1 1 24.6.10 0 0 0 0 0
130 tag2 0 0 29.6.10 0 0 0 0 0
131 t1g2 1 0 5.7.10 0 0 0 0 0
132 t1g2 1 0 6.7.10 0 0 0 0 0
133 t1g2 1 0 8.7.10 0 0 0 0 0
134 t1g2 1 0 13.12.10 0 0 0 0 0
135 tig3 1 1 10.4.10 0 0 0 0 0
136 t1g3 1 1 15.7.10 chr cyst 0 0 1 0
137 t1g3 1 1 11.10.10 0 0 0 0 0
138 t1g2 1 0 21.10.10 0 0 0 0 0
139 t1g2-3 1 1 19.7.10 0 0 0 0 0
140 tag2 1 0 4.11.10 0 0 0 0 0
141 tag2 1 0 19.7.10 0 0 2 0 0
142 t1g3 1 1 29.1.08 0 0 0 0 0
143 t1g3 1 1 20.7.10 0 0 0 0 0
144 t1g2 0 0 20.7.10 0 0 0 0 0
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145 tag2 1 0 21.7.10 0 0 0 0 0
146 tag2 1 0 22.7.10 t1g2 0 0 1 0
147 t1g3 0 1 22.7.10 bcg cystitis 0 0 1 0
148 tag2 0 0 26.7.10 0 1 0 0 0
149 ?tag2 0 0 27.7.10 0 0 0 0 0
150 tag2 1 0 29.7.10 0 0 0 0 0
151 tag3 1 0 30.7.10 0 0 0 0 0
152 tag3 1 0 17.12.10 0 0 0 0 0
153 t1g3 1 1 31.7.10 0 0 0 0 0
154 t1g2 1 0 5.8.10 0 0 0 0 0
155 t1g2 1 0 5.4.10 0 0 0 0 0
156 tag2 0 0 6.8.10 0 0 0 0 0
157 t1g2 1 0 9.8.10 0 0 0 0 0
158 tag2 1 0 15.11.10 0 0 0 0 0
159 tag2 1 0 9.8.10 0 0 0 0 0
160 t1g3 1 1 19.8.10 0 0 0 0 0
161 t1g3 0 1 15.11.10 0 0 0 0 0
162 t1g2 1 0 24.8.10 0 0 0 0 0
163 t1g3 1 1 24.8.10 0 0 0 0 0
164 tag2 1 0 27.8.10 0 0 0 0 0
165 t1g2 1 1 26.3.10 t1g2 0 0 1 0
166 t1g2 1 1 28.8.10 0 0 0 0 0
167 t2g3 1 1 30.8.10 0 0 0 0 0
168 tag2 0 0 10.9.10 0 0 0 0 0
169 t1g2 1 0 10.9.10 0 0 0 0 0
170 tag1 1 0 27.12.10 0 0 0 0 0
171 tag2 1 0 14.9.10 chr cyst 0 0 1 0
172 tig3 1 1 20.9.10 0 0 0 0 0
173 tag2 1 0 16.12.10 0 0 0 0 0
174 tag2 0 0 16.9.10 0 0 0 0 0
175 t1g2 1 0 17.9.10 0 0 0 0 0
176 tag2 1 0 20.9.10 0 0 0 0 0
177 t1g2 1 0 21.9.10 chr cyst 0 0 1 0
178 tag2 1 0 18.5.07 tag2 0 0 1 0
179 t1g3 1 1 23.9.10 chr cyst 0 0 1 0
180 t1g3 1 1 23.9.10 t1g3 0 0 1 0
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181 t1g3 1 1 27.9.10 0 0 0 0 0
182 t1g3 1 1 27.9.10 0 0 0 0 0
183 tag1 1 0 30.9.10 0 2 0 0 0
184 tag1 1 0 30.9.10 0 0 0 0 0
185 tag3cis 1 1 30.9.10 0 2 0 0 0
186 t1g3 1 1 9.4.10 0 0 0 0 1
187 t1g3 1 1 7.10.10 0 0 0 0 0
188 t1g2 1 0 11.10.10 t1g2 0 0 1 0
189 tag3 1 0 15.10.10 0 0 0 0 0
190 tag2 1 0 18.10.10 0 0 0 0 0
191 tag3 1 1 22.10.10 0 0 0 0 0
192 t1g3 0 1 28.10.10 0 0 0 0 0
193 t1g3 0 1 14.4.10 0 0 0 0 0
194 t1g3 1 1 29.10.10 0 0 0 0 0
195 t1g3 1 1 29.10.10 0 0 0 0 0
196 tag2 1 0 4.11.10 0 0 0 0 0
197 t1g3 0 1 8.11.10 0 0 0 0 0
198 tag2 1 0 10.11.10 0 0 0 0 0
199 t1g3 1 1 15.11.10 0 0 0 0 0
200 t1g3 1 1 15.11.10 0 0 0 0 0
201 tag2 1 0 22.11.10 tag21 0 0 1 0
202 tag2 1 0 25.11.10 0 0 0 0 0
203 tag2 0 0 25.11.10 0 0 0 1 0
204 tag2 1 0 31.3.10 tag2 0 1 1 0
205 tag2 0 0 6.12.10 0 0 0 0 0
206 tag2 1 0 7.12.10 0 0 0 0 0
207 t1g3 0 1 7.12.10 0 0 1 0 0
208 t1g3 1 1 9.6.10 t1g3 1 1 1 0
209 t1g3 1 1 16.12.10 chr cyst 1 0 1 0
210 t1g3 1 1 22.09.10 0 0 0 0 0
211 CIS 1 0 23.12.10 0 0 0 0 1
212 tag2 1 0 31.12.10 0 0 0 0 0
213 t1g3 1 1 19.4.10 0 0 0
214 t1g3 1 0 13.10.10 t1g3 1 1 1 0
215 t1g2 1 0 1.3.8.10 0 0 0 0 0
216 tag2 1 1 10.8.10 0 0 0 0 0
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217 t1g3 1 0 20.7.10 0 0 0 0 0
218 tag2 1 0 13.7.10 0 0 0 0 0
219 t1g2 1 0 8.6.10 0 0 0 0 0
220 tag2 1 0 16.7.10 0 0 0 0 0
221 t1g3 1 1 23.7.10 t1g3 0 0 1 0
222 tag2 1 0 22.7.10 tag2 0 0 1 0
223 t1g2 1 0 23.7.10 0 0 0 0 0
224 t1g2 1 0 22.7.10 0 0 0 0 0
225 t1g3 0 1 22.7.10 bcg cystitis 0 0 1 0
226 tag2 1 1 22.7.10 0 0 0 0 0
227 tag2 1 0 4.5.10 0 0 0 0 0
228 tag2 1 0 13.8.10 tag2 1 0 1 0
229 t1g3 1 1 20.9.10 0 0 0 0 0
230 t1g3 1 1 22.9.10 0 0 0 0 0
231 t1g3 1 1 8.6.10 0 0 0 0 0
232 tag2 0 0 5.8.10 0 1 0 0 0
233 tag2 0 0 3.1.11 0 0 0 0 0
234 tag2 0 0 16.7.10 0 0 0 0 0
235 tag2 1 0 6.4.10 0 0 0 0 0
236 tag2 1 0 8.4.10 0 0 0 0 0
237 tag2 0 0 8.4.10 0 0 0 0 0
238 tag2 0 0 8.4.10 0 0 0 0 0
239 t1g2 1 0 12.4.10 0 0 0 0 0
240 t1g2 1 0 14.4.10 0 0 0 0 0
241 t1g2 1 0 17.4.10 0 0 0 0 0
242 t1g3 1 1 27.4.10 0 0 0 0 0
243 t1g3 0 1 14.7.10 0 0 0 0 0
244 tag2 1 0 3.5.10 0 0 0 0 0
245 t1g2 1 1 16.8.10 0 0 0 0 0
246 t1g2 1 0 10.5.10 0 0 0 0 0
247 t1g3 0 1 13.5.10 0 0 0 0 0
248 t1g2 1 0 25.5.10 0 0 0 0 0
249 t1g3 1 1 17.1.11 0 0 0 0 0
250 t1g2 1 0 2.2.09 0 0 0 0 0
